Advertisement

Uroonkologie pp 637-738 | Cite as

Maligne Hodentumoren

  • Peter Albers
  • Jörg Beyer
  • Johannes Claßen
  • Klaus-Peter Dieckmann
  • Jörg T. Hartmann
  • Michael Hartmann
  • Axel Heidenreich
  • S. Krege
  • Marcus A. Kuczyk
  • Frank Mayer
  • Axel S. Merseburger
  • Siegfried Seeber
  • Rainer Souchon
  • Michael Stöckle

Zusammenfassung

Der testikuläre Keimzelltumor (KZT) repräsentiert den häufigsten bösartigen Tumor in der Altersgruppe der 20- bis 40-jährigen Männer. Die Altersverteilung des KZT unterscheidet sich von den übrigen soliden Neoplasien des Menschen dahingehend, dass ein erster Altersgipfel zwischen dem 25. und 35. Lebensjahr, ein zweiter geringerer Gipfel nach dem 80. Lebensjahr auftritt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Literatur zu Kap. 26.1

  1. Akre O, Ekbom A, Sparen P et al. (2000) Body size and testicular cancer. J Natl Cancer Inst 92: 1093–1096PubMedCrossRefGoogle Scholar
  2. Armstrong B, Doll R (1975) Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 15: 617–631PubMedCrossRefGoogle Scholar
  3. Brown LM, Pottern LM, Hoover RN et al. (1986) Testicular cancer in the United States: rends in incidence and mortality. Int J Epidemiol 15: 164–170PubMedCrossRefGoogle Scholar
  4. Cannon-Albright LA, Thomas A, Goldgar DE et al. (1994) Familiality of cancer in Utah. Cancer Res 54: 2378–2385PubMedGoogle Scholar
  5. Carlesen E, Giwercman A, Keiding N et al. (1992) Evidence for decreasing quality of semen during the last 50 years. BMJ 305: 609–612CrossRefGoogle Scholar
  6. Coupland CAC, Forman D, Chilvers CED et al. (2004) Maternal risk factors for testicular cancer: a population-based case control study (UK). Cancer Causes Control 15: 277–283PubMedCrossRefGoogle Scholar
  7. Davies TW, Palmer CR, Ruja E et al. (1996) Adolescent milk, dairy product and fruit consumption and testicular cancer. Br J Cancer 74: 657–660PubMedGoogle Scholar
  8. Dieckmann KP, Pichlmeier U (2002) Is risk of testicular cancer related to body size? Eur Urol 2: 564–569CrossRefGoogle Scholar
  9. Dieckmann KP, Pichlmeier U (2004) Clinical epidemiology of testicular germ cell tumors. World J Urol 22: 2–14PubMedCrossRefGoogle Scholar
  10. Ganmaa D, Li XM, Wang J et al. (2002) Incidence and mortality of testicular and prostatic cancers in relation to world dietary practices. Int J Cancer 98: 262–267PubMedCrossRefGoogle Scholar
  11. Garner MJ, Birkett NJ, Johnson KC (2003) Dietary risk factors for testicular carcinoma. Int J Cancer 106: 934–941PubMedCrossRefGoogle Scholar
  12. Garner MJ, Turner MC, Ghadiriam P et al. (2005) Epidemiology of testicular cancer: an overview. Int J Cancer 116: 331–339PubMedCrossRefGoogle Scholar
  13. Giwercman A, Grindsted J, Hansen B et al. (1987) Testicular cancer risk in boys with maldescended testis: a cohort study. J Urol 138: 1214–1216PubMedGoogle Scholar
  14. Giwercman A, Muller J, Skakkebaek NE (1988) Cryptorchidism and testicular neoplasia. Horm Res 30: 157–163PubMedCrossRefGoogle Scholar
  15. Haughey BP, Graham S, Brasure J et al. (1989) The epidemiology of testicular cancer in upstate New York. Am J Epidemiol 130: 25–36PubMedGoogle Scholar
  16. Heimdahl K, Olsson H, Tretli S et al. (1996) Familial testicular cancer in Norway and southern Sweden. Br J Cancer 73: 964–969Google Scholar
  17. Huyghe E, Matsuda T, Thonneau P (2003) Increasing incidence of testicular cancer worldwide: a review. J Urol 170: 5–11PubMedCrossRefGoogle Scholar
  18. Jacobsen R, Bostofte E, Engholm G et al. (2000) Risk of testicular cancer in men with abnormal semen characteristics: cohort study. BMJ 321: 789–792PubMedCrossRefGoogle Scholar
  19. McKierman JM, Goluboff ET, Liberson GL et al. (1999) Rising risk of testicular cancer by birth cohort in the United States from 1973 to 1995. J Urol 162: 361–367CrossRefGoogle Scholar
  20. Moller H (1997) Work in agriculture, childhood resistance, nitrate exposure, and testicular cancer risk: a case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 6: 141–144PubMedGoogle Scholar
  21. Moller H, Skakkebaek NE (1996) Risk of testicular cancer and cryptorchidism in relation to socioeconomic status and related factors: case — control studies in Denmark. Int J Cancer 66: 287–293PubMedCrossRefGoogle Scholar
  22. Moller H, Jorgensen N, Fordham D (1995) Trends in incidence of testicular cancer in boys and adolescent men. Int J Cancer 61: 761–764PubMedCrossRefGoogle Scholar
  23. Moss AR, Osmond D, Bachetti P et al. (1986) Hormonal risk factors in testicular cancer. A case control study. Am J Epidemiol 124: 39–52PubMedGoogle Scholar
  24. Oesterlind A (1986) Diverging trends in incidence and mortality of testicular cancer in Denmark 1943–1982. Br J Cancer 53: 501–505Google Scholar
  25. Parkin DM, Shanmugarathnam K, Sobin L et al. (1998) Histological groups for comparative studies. Lyon: IARCGoogle Scholar
  26. Pearce N, Sheppard RA, Howard JK et al. (1987) Time trends and occupational differences in cancer of the testis in New Zealand. Cancer 59: 1677–1682PubMedCrossRefGoogle Scholar
  27. Pottern LM, Morris Brown L, Hoover RN et al. (1985) Testicular cancer risk among young men: role of cryptorchidism and inguinal hernia. J Natl Cancer Inst 74: 377–381PubMedGoogle Scholar
  28. Prener A, Hsieh AA, Engholm G et al. (1992) Birth order and risk of testicular cancer. Cancer Causes Control 3: 265–272PubMedCrossRefGoogle Scholar
  29. Rapley EA, Crockford GP, Teare D et al. (2000) Localisation to Xq27 of a susceptibility gene for testicular germ-cell tumors. Nat Genet 24: 197–200PubMedCrossRefGoogle Scholar
  30. Richiardi L, Askling J, Granath F et al. (2003) Body size at birth and adulthood and the risk for germ-cell testicular cancer. Cancer Epidemiol Biomarkers Prev 12: 669–673PubMedGoogle Scholar
  31. Richiardi L, Akre O, Lambe M et al. (2004) Birth order, sidship size, and risk for germ-cell testicular cancer. Epidemiology 15: 323–329PubMedCrossRefGoogle Scholar
  32. Rorth M, Rajpert-De Meyts E, Andersson L et al. (2000) Carcinoma in situ in the testis. Scand J Urol Nephrol Suppl: 166–186Google Scholar
  33. Sharpe RM, Skakkebaek NE (1993) Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? Lancet 341: 1392–1395PubMedCrossRefGoogle Scholar
  34. Sigurdson AJ, Chang S, Annegers JF et al. (1999) A case-control study of diet and testicular carcinoma. Nutr Cancer 34: 20–26PubMedCrossRefGoogle Scholar
  35. Swerdlow AJ, Skeet RG (1988) Occupational associations of testicular cancer in South East England. Br J Ind Med 45: 225–230PubMedGoogle Scholar
  36. Swerdlow AJ, Huttly SR, Smith P (1989) Testis cancer: post-natal hormonal factors, sexual behaviour and fertility. Int J Cancer 43: 549–553PubMedCrossRefGoogle Scholar
  37. Swerdlow AJ, Higgins CD, Pike MC (1997) Risk of testicular in a cohort of boys with cryptorchidism. BMJ 314: 1507–1511PubMedGoogle Scholar
  38. Troisi R, Potischman N, Roberts J et al. (2003) Associations of maternal and umbilical cord hormone concentrations with maternal gestational and neonatal factors (United States). Cancer Causes Control 14: 347–355PubMedCrossRefGoogle Scholar
  39. United Kingdom Testicular Cancer Study Group (1994) Aetiology of testicular cancer: association with congenital abnormalities, age at puberty, infertility and exercise. BMJ 308: 1393–1399Google Scholar
  40. Wanderas EH, Tretli S, Fossa SD (1995) Trends in incidence of testicular cancer in Norway 1955–1992. Eur Urol 31A: 2044–2048Google Scholar
  41. Wanderas EH, Grotmol T, Fossa SD et al. (1998) Maternal health and pre-and perinatal characteristics in the etiology of testicular cancer: a prospective population and register-based study on Norwegian male bons between 1967 and 1995. Cancer Causes Control 9: 475–486PubMedCrossRefGoogle Scholar
  42. Weir HK, Marrett LD, Kreiger N et al. (2000) Prenatal and perinatal exposures and risk of testicular germ cell cancer. Int J Cancer 87: 438–443PubMedCrossRefGoogle Scholar
  43. Westergaard T, Olsen JH, Frisch M et al. (1996) Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population-based study. Int J Cancer 66: 627–631PubMedCrossRefGoogle Scholar
  44. Westergaard T, Andersen PK, Pedersen JB et al. (1998) Testicular cancer risk and maternal parity: a population-based cohort study. Br J Cancer 77: 1180–1185PubMedGoogle Scholar

Literatur zu Kap. 26.2

  1. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56: 3087–3090PubMedGoogle Scholar
  2. Aebi S, Fink D, Gordon R, Kim HK, Zheng H, Fink JL, Howell SB (1997) Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 3: 1763–1767PubMedGoogle Scholar
  3. Antonsson B, Martinou JC (2000) The Bcl-2 protein family. Exp Cell Res 256: 50–57PubMedCrossRefGoogle Scholar
  4. Bernstein C, Bernstein H, Payne CM, Garewal H (2002) DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 511: 145–178PubMedCrossRefGoogle Scholar
  5. Bokemeyer C, Nichols CR, Droz JP, Schmoll HJ, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Kanz L, Einhorn L, Hartmann JT (2002) Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol 20: 1864–1873PubMedCrossRefGoogle Scholar
  6. Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92: 1295–1302PubMedCrossRefGoogle Scholar
  7. Bosl GH, Goldman A, Lange PH et al. (1981) Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet 2: 970–973PubMedCrossRefGoogle Scholar
  8. Burger H, Nooter K, Boersma AW, Kortland CJ, Stoter G (1997) Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines. Int J Cancer 73: 592–599PubMedCrossRefGoogle Scholar
  9. Burger H, Nooter K, Boersma AW, van Wingerden KE, Looijenga LH, Jochemsen AG, Stoter G (1999) Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines. Int J Cancer 81: 620–628PubMedCrossRefGoogle Scholar
  10. Cairns J (2002) Somatic stem cells and the kinetics of mutagenesis and carcinogenesis. Proc Natl Acad Sci USA 99: 10567–10570PubMedCrossRefGoogle Scholar
  11. Chaganti RS, Houldsworth J (2000) Genetics and biology of adult human male germ cell tumors. Cancer Res 60: 1475–1482PubMedGoogle Scholar
  12. Chresta CM, Masters JR, Hickman JA (1996) Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 56: 1834–1841PubMedGoogle Scholar
  13. Conrad S, Renninger M, Hennenlotter J, Wiesner T, Just L, Bonin M, Aicher W, Buhring HJ, Mattheus U, Mack A, Wagner HJ, Minger S, Matzkies M, Reppel M, Hescheler J, Sievert KD, Stenzl A, Skutella T (2008) Generation of pluripotent stem cells from adult human testis. Nature 456:344–349PubMedCrossRefGoogle Scholar
  14. de Jong J, Stoop H, Dohle GR, Bangma CH, Kliffen M, van Esser JW, van den BM, Kros JM, Oosterhuis JW, Looijenga LH (2005) Diagnostic value of OCT3/4 for pre-invasive and invasive testicular germ cell tumours. J Pathol 206: 242–249PubMedCrossRefGoogle Scholar
  15. Devouassoux-Shisheboran M, Mauduit C, Bouvier R, Berger F, Bouras M, Droz JP, Benahmed M (2001) Expression of hMLH1 and hMSH2 and assessment of microsatellite instability in testicular and mediastinal germ cell tumours. Mol Hum Reprod 7: 1099–1105PubMedCrossRefGoogle Scholar
  16. Dieckmann KP, Becker T, Bauer HW (1987) Testicular tumors. Presentation and role of diagnostic delay. Urol Int 42: 241PubMedGoogle Scholar
  17. Dieckmann KP, Krain J, Gottschalk W et al. (1994) Atypische Symptomatik bei Patienten mit germinalen Hodentumoren. Urol A 33: 325–330Google Scholar
  18. Faulkner SW, Friedlander ML (2000) Microsatellite instability in germ cell tumors of the testis and ovary. Gynecol Oncol 79: 38–43PubMedCrossRefGoogle Scholar
  19. Fink D, Nebel S, Norris PS, Baergen RN, Wilczynski SP, Costa MJ, Haas M, Cannistra SA, Howell SB (1998) Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer 77: 741–746PubMedCrossRefGoogle Scholar
  20. Gondos B (1993) Ultrastructure of developing and malignant germ cells. Eur Urol 23: 68–74PubMedGoogle Scholar
  21. Gondos B, Migliozzi JA (1987) Intratubular germ cell neoplasia. Semin Diagn Pathol 4: 292–303PubMedGoogle Scholar
  22. Hainaut P, Soussi T, Shomer B, Hollstein M, Greenblatt M, Hovig E, Harris CC, Montesano R (1997) Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res 25: 151–157PubMedCrossRefGoogle Scholar
  23. Hamm B (1997) Differential diagnosis of scrotal masses by ultrasound. Eur Radiol 7: 668–679PubMedCrossRefGoogle Scholar
  24. Hardman RA, Afshari CA, Barrett JC (2001) Involvement of mammalian MLH1 in the apoptotic response to peroxide-induced oxidative stress. Cancer Res 61: 1392–1397PubMedGoogle Scholar
  25. Honecker F, Mayer F, Stoop H, Oosterhuis JW, Koch S, Bokemeyer C, Looijenga LH (2003) Xeroderma pigmentosum group a protein and chemotherapy resistance in human germ cell tumors. Lab Invest 83: 1489–1495PubMedCrossRefGoogle Scholar
  26. Honecker F, Mayer F, Stoop H, Oosterhuis JW, Koch S, Bokemeyer C, Looijenga LH (2003) Xeroderma pigmentosum group a protein and chemotherapy resistance in human germ cell tumors. Lab Invest 83 1489–1495PubMedCrossRefGoogle Scholar
  27. Houldsworth J, Xiao H, Murty VV, Chen W, Ray B, Reuter VE, Bosl GJ, Chaganti RS (1998) Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 16: 2345–2349PubMedCrossRefGoogle Scholar
  28. Huddart RA, Wooster R, Horwich A, Cooper CS (1995) Microsatellite instability in human testicular germ cell tumours. Br J Cancer 72: 642–645PubMedGoogle Scholar
  29. Ise T, Shimizu T, Lee EL, Inoue H, Kohno K, Okada Y (2005) Roles of volume-sensitive Cl-channel in cisplatin-induced apoptosis in human epidermoid cancer cells. J Membr Biol 205: 139–145PubMedCrossRefGoogle Scholar
  30. Jacob S, Aguado M, Fallik D, Praz F (2001) The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res 61: 6555–6562PubMedGoogle Scholar
  31. Kersemaekers AM, Mayer F, Molier M, van Weeren PC, Oosterhuis JW, Bokemeyer C, Looijenga LH (2002) Role of P53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol 20: 1551–1561PubMedCrossRefGoogle Scholar
  32. Kishimoto S, Kawazoe Y, Ikeno M, Saitoh M, Nakano Y, Nishi Y, Fukushima S, Takeuchi Y (2006) Role of Na+, K+-ATPase alpha 1 subunit in the intracellular accumulation of cisplatin. Cancer Chemother Pharmacol 57: 84–90PubMedCrossRefGoogle Scholar
  33. Kitada N, Takara K, Minegaki T, Itoh C, Tsujimoto M, Sakaeda T, Yokoyama T (2008) Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines. Cancer Chemother. Pharmacol. 62: 577–584PubMedCrossRefGoogle Scholar
  34. Kliesch S (2004) Diagnostik und Primärtherapie des Hodentumors. Urol A 43: 1494–1499CrossRefGoogle Scholar
  35. Kliesch S, Bermann M, Hertle L et al. (1997) Semen parameters and testicular pathology in men with testicular cancer and contralateral carcinoma in situ or bilateral testicular malignancies. Hum Reprod 12: 2830–2835PubMedCrossRefGoogle Scholar
  36. Koberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JR (1997) DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 70: 551–555PubMedCrossRefGoogle Scholar
  37. Koberle B, Masters JR, Hartley JA, Wood RD (1999) Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 9: 273–276PubMedCrossRefGoogle Scholar
  38. Koberle B, Roginskaya V, Zima KS, Master JR, Wood RD (2008) Elevation of XPA protein level in testis tumor cells without increasing resistance to cisplatin or UV radiation. Mol. Carcinog 47:580–586PubMedCrossRefGoogle Scholar
  39. Konig J, Nies AT, Cui Y, Leier I, Keppler D (1999) Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1461: 377–394PubMedCrossRefGoogle Scholar
  40. Lage H, Dietel M (1999) Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J Cancer Res Clin Oncol 125: 156–165PubMedCrossRefGoogle Scholar
  41. Looijenga LH, Oosterhuis JW (1999) Pathogenesis of testicular germ cell tumours. Rev Reprod 4: 90–100PubMedCrossRefGoogle Scholar
  42. Lothe RA, Peltomaki P, Tommerup N, Fossa SD, Stenwig AE, Borresen AL, Nesland JM (1995) Molecular genetic changes in human male germ cell tumors. Lab Invest 73: 606–614PubMedGoogle Scholar
  43. Lutzker SG, Levine AJ (1996) A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat Med 2: 804–810PubMedCrossRefGoogle Scholar
  44. Lutzker SG, Mathew R, Taller DR (2001) A p53 dose-response relationship for sensitivity to DNA damage in isogenic teratocarcinoma cells. Oncogene 20: 2982–2986PubMedCrossRefGoogle Scholar
  45. Masters JR, Thomas R, Hall AG, Hogarth L, Matheson EC, Cattan AR, Lohrer H (1996) Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. Eur J Cancer 32A, 1248–1253PubMedCrossRefGoogle Scholar
  46. Mayer F, Gillis AJ, Diniens W, Oosterhuis JW, Bokemeyer C, Looijenga LH (2002) Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res 62: 2758–2760PubMedGoogle Scholar
  47. Mayer F, Stoop H, Scheffer GL, Scheper R, Oosterhuis JW, Looijenga LH, Bokemeyer C (2003) Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res 9: 767–773PubMedGoogle Scholar
  48. McGurk CJ, Cummings M, Koberle B, Hartley JA, Oliver RT, Masters JR (2006) Regulation of DNA repair gene expression in human cancer cell lines. J Cell Biochem 97: 1121–1136PubMedCrossRefGoogle Scholar
  49. Mostert MC, Verkerk AJ, van de PM, Heighway J, Marynen P, Rosenberg C, van Kessel AG, van Echten J, de Jong B, Oosterhuis JW, Looijenga LH (1998) Identification of the critical region of 12p overrepresentation in testicular germ cell tumors of adolescents and adults. Oncogene 16: 2617–2627PubMedCrossRefGoogle Scholar
  50. Mostofi FK (1973) Proceedings: Testicular tumors. Epidemiologic, etiologic, and pathologic features. Cancer 32: 1186–1201PubMedCrossRefGoogle Scholar
  51. Moul JW, Paulson DF, Dodge RK et al. (1990) Delay in diagnostic and survival in testicular cancer: impact of effective therapy and changes during 18 years. J Urol 1990: 520–523Google Scholar
  52. Mueller S, Schittenhelm M, Honecker F, Malenke E, Lauber K, Wesselborg S, Hartmann JT, Bokemeyer C, Mayer F (2006) Cell-cycle progression and response of germ cell tumors to cisplatin in vitro. Int J Oncol 29: 471–479PubMedGoogle Scholar
  53. Nikzas S, Champion AE, Fox M (1990) Germ cell tumors of testis: prognostic factors and results. Eur Urol 18: 242PubMedGoogle Scholar
  54. Oosterhuis JW, Looijenga LH (2005) Testicular germ-cell tumours in a broader perspective. Nat. Rev. Cancer 5: 210–222PubMedCrossRefGoogle Scholar
  55. Oliver RTD (1985) Factors contributing to delay in diagnosis of testicular tumors. Brit Med J 290: 356CrossRefGoogle Scholar
  56. Oosterhuis JW, Looijenga LH, van Echten J, de Jong B (1997) Chromosomal constitution and developmental potential of human germ cell tumors and teratomas. Cancer Genet Cytogenet 95: 96–102PubMedCrossRefGoogle Scholar
  57. Ottesen AM, Skakkebaek NE, Lundsteen C, Leffers H, Larsen J, Rajpert-De Meyts E (2003) High-resolution comparative genomic hybridization detects extra chromosome arm 12p material in most cases of carcinoma in situ adjacent to overt germ cell tumors, but not before the invasive tumor development. Genes Chromosomes Cancer 38: 117–125PubMedCrossRefGoogle Scholar
  58. Prout GR, Griffin PP (1984) Testicular tumors; delay in diagnosis and influence in survival. Am J Fam Phys 29: 205–209Google Scholar
  59. Rajpert-De Meyts E, Bartkova J, Samson M, Hoei-Hansen CE, Frydelund-Larsen L, Bartek J, Skakkebaek NE (2003) The emerging phenotype of the testicular carcinoma in situ germ cell. APMIS 111: 267–278PubMedCrossRefGoogle Scholar
  60. Reed E (1998) Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24: 331–344PubMedCrossRefGoogle Scholar
  61. Rosenberg C, van Gurp RJ, Geelen E, Oosterhuis JW, Looijenga LH (2000) Overrepresentation of the short arm of chromosome 12 is related to invasive growth of human testicular seminomas and nonseminomas. Oncogene 19: 5858–5862PubMedCrossRefGoogle Scholar
  62. Sandberg AA, Meloni AM, Suijkerbuijk RF (1996) Reviews of chromosome studies in urological tumors. III. Cytogenetics and genes in testicular tumors. J Urol 155: 1531–1556PubMedCrossRefGoogle Scholar
  63. Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ (1995) The drug resistance-related protein LRP is the human major vault protein. Nat Med 1: 578–582PubMedCrossRefGoogle Scholar
  64. Schmoll HJ, Souchon R, Krege S et al. (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European germ cell cancer consensus group (EGCCCG). Ann Oncol 15: 1377–1399PubMedCrossRefGoogle Scholar
  65. Skakkebaek NE (1972) Possible carcinoma-in-situ of the testis. Lancet 2: 516–517PubMedCrossRefGoogle Scholar
  66. Spierings DC, de Vries EG, Vellenga E, de Jong S (2003a) Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line. Cell Death Differ 10: 808–822PubMedCrossRefGoogle Scholar
  67. Spierings DC, de Vries EG, Vellenga E, de Jong S (2003b) The attractive Achilles heel of germ cell tumors an inherent sensitivity to apoptosis-inducing stimuli. J Pathol 200(2): 137–148PubMedCrossRefGoogle Scholar
  68. Strohmeyer T, Reissmann P, Cordon-Cardo C, Hartmann M, Ackermann R, Slamon D (1991) Correlation between retinoblastoma gene expression and differentiation in human retionablastoma gene expression and differentiation in human testicular tumors. Proc Natl Acad Sci USA 88: 6662–6666PubMedCrossRefGoogle Scholar
  69. Ulbright TM (1993) Germ cell neoplasms of the testis. Am J Surg Pathol 17: 1075–1091PubMedCrossRefGoogle Scholar
  70. Velasco A, Riquelme E, Schultz M, Wistuba II, Villaroel L, Pizarro J, Berlin A, Ittamann M, Koh MS, Leach FS (2004) Mismatch repair gene expression and genetic instability in testicular germ cell tumor. Cancer Biol Ther 3: 977–982PubMedGoogle Scholar
  71. Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel J, Liu VP, van Duijse J, Drost J, Griekspoor A, Zlotorynski E, Yabuta N, De Vita G, Nojima H, Looijenga LH, Agami R (2006) A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 124: 1169–1181PubMedCrossRefGoogle Scholar
  72. Wylie C (1999) Germ cells. Cell 96: 165–174PubMedCrossRefGoogle Scholar

Literatur zu Kap. 26.3

  1. Canil CM, Tannock IF (2002) Doctor’s dilemna: incorporating tumor makers into clinical decision-making. Semin Oncol 29: 286–293PubMedCrossRefGoogle Scholar
  2. DeSantis M, Bokemeyer C Becherer A et al. (2001) Predictive impact of 2–18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 19: 3740–3744Google Scholar
  3. Dieckmann KP, Loy V (1996) Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol 14: 3126–3132PubMedGoogle Scholar
  4. Dieckmann KP, Kulejewski M, Pichlmeier U, Loy V (2007) PatDiagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol 51: 175–185PubMedCrossRefGoogle Scholar
  5. Hamm B (1997) Differential diagnosis of scrotal masses by ultrasound. Eur Radiol 7: 668–679PubMedCrossRefGoogle Scholar
  6. Holm M, Hoei-Hansen CE, Rajpert-de Meyts E et al. (2003) Increased risk of carcinoma in situ in patients with testicular germ cell cancer with ultrasonic microlithiasis in the contralateral testicle. J Urol 170: 1163–1167PubMedCrossRefGoogle Scholar
  7. Huddart R, O’Doherty M, Padhani A et al. (2008) A prospective study of 18FDG PET in the prediction of relapse in patients with stage I (CSI) non-seminomatous germ cell cancer (NSGCT): MRC study TE22. ASCO. abstract 4520Google Scholar
  8. International Germ Cell Cancer Collaborative Group (IGCCCG) (1997) The International Germ Cell Consensus Classification: A prognostic factor based staging system for metastatic germ cell cancer. J Clin Oncol 15: 594–603Google Scholar
  9. Jacobson GK, Norgaard Pedersen B (1986) Placental alkaline phosphatase in testicular germ cell tumours and in carcinoma-in-situ of the testis. In: Jones WG, Milford WA, Anderson CK (eds) Germ cell tumours II. Pergamon, Oxford, p 157Google Scholar
  10. Kliesch S (2003) Fertilität bei Patienten mit Hodentumorerkrankungen. Onkologe 9: 955–961CrossRefGoogle Scholar
  11. Krug B, Heidenreich A, Dietlein M et al. (1999) Lymphknotenstaging maligner testikulärer Keimzelltumoren Fortschr Röntgenstr 171: 87–94CrossRefGoogle Scholar
  12. Lassen, U, Daugaard G, Eigtved A et al. (2003) Wholebody positron emission tomography (PET) with FDG in patients with stage I non-seminomatous germ cell tumours (NSGCT). Eur J Nucl Med Imaging 30: 396–402Google Scholar
  13. May M, Helke C, Nitzke T et al. (2004) Diagnostic value of tumour marker regression models in stage I marker-positive testicular cancer. Urol Int 73: 329–336PubMedCrossRefGoogle Scholar
  14. Mazumdar M, Bajorin DF, Bacik J et al. (2001) Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotropin and alphafetoprotein during therapy. J Clin Oncol 19: 2534–2541PubMedGoogle Scholar
  15. Meyer CA, Conces DJ (2002) Imaging of intrathoracic metastases of nonseminomatous germ cell tumors. Chest Surg Clin N Am 12: 717–738PubMedGoogle Scholar
  16. Nagler-Reus M, Guhl L, Volz C, Wuerstlin S, Arlart IP (1995) Magnetic resonance tomography of the scrotum. Experiences with 129 patients. Radiologe 8: 494–503Google Scholar
  17. Nicolai N, Miceli R, Artusi R et al. (2004) A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only. J Urol 171: 172–176PubMedCrossRefGoogle Scholar
  18. Salesi N, Di Cocco B, Alghisi F et al. (2002) Testis cancer markers. Clinical use. Minerva Med 93: 365–369PubMedGoogle Scholar
  19. Schmidt KL, Larsen E, Bangsboll S et al. (2004) Assisted reproduction in male cancer survivors: fertility treatment and outcome in 67 couples. Hum Reprod 19: 2806–2810PubMedCrossRefGoogle Scholar
  20. Sobin, LH, Wittekind, Ch (eds.) (2002) UICC: TNM classification of malignant tumours. Sixth edition. Wiley-Liss, Inc., New YorkGoogle Scholar
  21. White PM, Adamson DJA, Howard GCW et al. (1999) Imaging of the thorax in the management of germ cell testicular tumours. Clin Radiol 54: 207–211PubMedCrossRefGoogle Scholar

Literatur zu Kap. 26.4

  1. Al-Assiri M, Kevin Z, Binsaleh S, Chan PT (2005) Surgical approach of giant testicular cancer. Case report and literature review. Can J Urol 12: 2557–9PubMedGoogle Scholar
  2. Albers P (2006) Organ-sparing surgery for testicular lesions. Eur Urol suppl 5: 522–524CrossRefGoogle Scholar
  3. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Horwich A, Klepp O, Laguna MP, Pizzocaro G (2005) Guidelines on testicular cancer. Eur Urol 48: 885–894PubMedCrossRefGoogle Scholar
  4. Albers P, Dieckmann K-P (1998) Hodentumoren: Diagnostik und Therapie des Primärtumors. Onkologe 4: 487–493CrossRefGoogle Scholar
  5. Albers P, Dommer K, Müller SC (1998) Hodentumoren — Todesfälle und Rezidive nach inadäquater Therapie. Testicular tumors. Mortality and recurrence after inadequate therapy. [Article in German]. Urologe A 37: 625–628PubMedCrossRefGoogle Scholar
  6. Ashdown DA, Bodiwala D, Liu S (2004) Is high cord radical orchidectomy always necessary for testicular cancer? Ann R Coll Surg Engl 86: 289–291PubMedCrossRefGoogle Scholar
  7. Azzopardi JG, Mostofi FK, Theiss EA (1961) Lesions of the testes observed in certain patients with widespread choriocarcinoma and related tumors. The significance and genesis of hematoxylin-staining bodies in the human testis. Am J Pathol 38: 207–225PubMedGoogle Scholar
  8. Bell D, Morash C, Dranitsaris G, Izawa J, Short T, Klotz LH, Fleshner N (2006) Does prolonging the time to testicular cancer surgery impact long-term cancer control: a systematic review of the literature. Can J Urol 13 Suppl 3: 30–6PubMedGoogle Scholar
  9. Bodiwala D, Summerton DJ, Terry TR (2007) Testicular prostheses: development and modern usage. Ann R Coll Surg Engl 89: 349–353PubMedCrossRefGoogle Scholar
  10. Boileau MA, Steers WD (1984) Testis tumors: the clinical significance of the tumor-contaminated scrotum. J Urol 132: 51–54PubMedGoogle Scholar
  11. Bolten M, Weissbach L, Kaden R (2005) Kryokonservierte humane Spermadepots. Brauchbarkeit nach jahrzehntelanger Lagerung. Urologe A 44: 904–908PubMedCrossRefGoogle Scholar
  12. Boy D, Carl P (2002) Akzeptanz von Silikonhodenprothesen im Langzeitverlauf. Urologe A 41: 462–469PubMedCrossRefGoogle Scholar
  13. Brydoy M, Fossa SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Dahl O (2005) Paternity following treatment for testicular cancer. J Natl Cancer Inst 97: 1580–1588PubMedCrossRefGoogle Scholar
  14. Buse S, Lurati G, Schmid HP (2003) Hodentumoren — eine aktuelle Übersicht. Schweiz Rundsch Med Prax 92: 1989–1997Google Scholar
  15. Capelouto CC, Clark PE, Ransil BJ, Loughlin KR (1995) A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? J Urol 153: 981–985PubMedCrossRefGoogle Scholar
  16. Casella R, Rochlitz C, Sauter G, Gasser TC (1999) Der »ausgebrannte« Hodentumor; eine seltene Erscheinungsform der Keimzellneoplasien. Schweiz Med Wochenschr 129: 235–240PubMedGoogle Scholar
  17. Chapple A, McPherson A (2004) The decision to have a prosthesis: A qualitative study of men with testicular cancer. Psychooncology 13: 654–664PubMedCrossRefGoogle Scholar
  18. Christensen TB, Daugaard G, Geertsen PF, von der Maase H (1998) Effect of chemotherapy on carcinoma in situ of the testis. Ann Oncol 9: 657–660PubMedCrossRefGoogle Scholar
  19. Colpi GM, Carmignani L, Nerva F, Guido P, Gadda F, Castiglioni F (2005) Testicular-sparing microsurgery for suspected testicular masses. BJU Int 96: 67–69PubMedCrossRefGoogle Scholar
  20. Daneshmand S, Skinner EC (2003) Surgery for testicular cancer: radical orchiectomy. In: Raghavan D (ed) American Cancer Society Atlas of Clinical Oncology — Germ Cell Tumors, pp 93–97. Decker, HamiltonGoogle Scholar
  21. Dieckmann K-P (2000) Die kontralaterale Hodenbiopsie beim Hodentumor — ein Plädoyer dafür. Urologe A 39: 260–266PubMedCrossRefGoogle Scholar
  22. Dieckmann KP (2007) diagnostic delay in testicular cancer: an analytic chimaera or a worthy goal? Eur Urol 52: 1566–1568PubMedCrossRefGoogle Scholar
  23. Dieckmann KP, Loy V (1993) Seminoma testis after testis sparing excision of testicular teratoma. Br J Urol 71: 612–613PubMedCrossRefGoogle Scholar
  24. Dieckmann KP, Loy V (1996) Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol 14: 3126–3132PubMedGoogle Scholar
  25. Dieckmann KP, Loy V (2003) False-Negative Biopsies for the Diagnosis of Testicular Intraepithelial Neoplasia (TIN) — An, Update. Eur Urol 43:516–521PubMedCrossRefGoogle Scholar
  26. Dieckmann KP, Becker T, Bauer HW (1987) Testicular tumors: presentation and role of diagnostic delay. Urol Int 42: 241–247PubMedCrossRefGoogle Scholar
  27. Dieckmann KP, Classen J, Loy V (2003) Diagnosis and management of testicular intraepithelial neoplasia (carcinoma in situ)—surgical aspects. APMIS 111: 64–68PubMedCrossRefGoogle Scholar
  28. Dieckmann KP, Claßen J, Loy V (2005a) Präkanzerose der Hodentumoren: Testikuläre intraepitheliale Neoplasie. Dtsch Ärztebl 102: A3106–A3109Google Scholar
  29. Dieckmann KP, Heinemann V, Frey U, Pichlmeier U (2005b) How Harmful is Contralateral Testicular Biopsy?-An Analysis of Serial Imaging Studies and a Prospective Evaluation of Surgical Complications. Eur Urol 48: 662–672PubMedCrossRefGoogle Scholar
  30. Dieckmann KP, Kulejewski M, Pichlmeier U, Loy V (2007) Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol 51: 175–185PubMedCrossRefGoogle Scholar
  31. Elert A, Olbert P, Hegele A, Barth P, Hofmann R, Heidenreich A (2002) Accuracy of frozen section examination, of testicular tumors of uncertain origin. Eur Urol 41: 290–3PubMedCrossRefGoogle Scholar
  32. El-Helw L, Coleman RE (2005) Salvage dose intense and high-dose chemotherapy for the treatment of poor prognosis or recurrent germ cell tumours. Cancer Treat Rev 31: 197–209PubMedCrossRefGoogle Scholar
  33. Fabre E, Jira H, Izard V, Ferlicot S, Hammoudi Y, Theodore C, Di Palma M, Benoit G, Droupy S (2004) »Burned-out’ primary testicular cancer. BJU Int 94: 74–78PubMedCrossRefGoogle Scholar
  34. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ (2008) Medical treatment of advanced testicular cancer. JAMA 299: 672–684PubMedCrossRefGoogle Scholar
  35. Fossa SD, Aass N, Heilo A, Daugaard G, Skakkebaek NE, Stenwig AE, Nesland JM, Looijenga LH, Oosterhuis JW (2003) Testicular carcinoma in situ in patients with extragonadal germ-cell tumours: the clinical role of pretreatment biopsy. Ann Oncol 14: 1412–1418PubMedCrossRefGoogle Scholar
  36. Fossa SD, Chen J, Schonfeld SJ, McGlynn KA, McMaster ML, Gail MH Travis LB (2005) Risk of contralateral testicular cancer: a population-based study of 29515 U.S. men. J Natl Cancer Inst 97: 1056–1066PubMedCrossRefGoogle Scholar
  37. Geczi L, Gomez F, Bak M, Bodrogi I (2003) The incidence prognosis clinical and histological characteristics treatment and outcome of patients with bilateral germ cell testicular cancer in Hungary. J Cancer Res Clin Oncol 129: 309–315PubMedGoogle Scholar
  38. Geldart TR, Simmonds PD, Mead GM (2002) Orchidectomy after chemotherapy for patients with metastatic testicular germ cell cancer. BJU Int 90: 451–455PubMedCrossRefGoogle Scholar
  39. Goldstein M, Waterhouse K (1983) When to use the Chevassu maneuver during exploration of intrascrotal masses. J Urol 130: 1199–1200PubMedGoogle Scholar
  40. Harding M, Paul J, Kaye SB (1995) Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours? Br J Urol 76: 491–494PubMedCrossRefGoogle Scholar
  41. Harland SJ, Cook PA, Fossa SD, Horwich A, Mead GM, Parkinson MC Roberts JT, Stenning SP (1998) Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: Defining a high risk group. J Urol 160: 1353–1357PubMedCrossRefGoogle Scholar
  42. Hartmann JT, Albrecht C, Schmoll HJ, Kuczyk MA, Kollmannsberger C, Bokemeyer C (1999) Long-term effects on sexual function and fertility after treatment of testicular cancer. Br J Cancer 80: 801–807PubMedCrossRefGoogle Scholar
  43. Hartmann JT, Fossa SD, Nichols CR, Droz JP, Horwich A, Gerl A, Beyer J, Pont J, Fizazi K, Hecker H, Kanz L, Einhorn L, Bokemeyer C (2001) Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. J Natl Cancer Inst 93: 1733–1738PubMedCrossRefGoogle Scholar
  44. Heidenreich A, Krege S, Flasshove M (2004) Interdisziplinäre Kooperation in der Therapie von komplexen Patienten mit fortgeschrittenem testikulärem Keimzelltumor. Urologe A 43: 1521–1530PubMedCrossRefGoogle Scholar
  45. Heidenreich A, Moul JW (2002) Contralateral testicular biopsy procedure in patients with unilateral testis cancer: Is it indicated? Semin Urol Oncol 20: 234–238PubMedCrossRefGoogle Scholar
  46. Heidenreich A, Weissbach L, Höltl W, Albers P, Kliesch S, Köhrmann KU, Dieckmann KP (2001) Organ Sparing Surgery for malignant Germ Cell Tumors of the Testis. J Urol 166: 2161–2165PubMedCrossRefGoogle Scholar
  47. Heidenreich A, Zumbe J, Vorreuther R, Klotz T, Vietsch H, Engelmann UH (1996) Testikuläre Epidermiszyste: Orchiektomie oder Enukleationsresektion? Urologe A 35: 1–5PubMedGoogle Scholar
  48. Hentrich M, Weber N, Bergsdorf T, Liedl B, Hartenstein R, Gerl A (2005) Management and outcome of bilateral testicular germ cell tumors: Twenty-five year experience in Munich. Acta Oncol 44: 529–536PubMedCrossRefGoogle Scholar
  49. Hermanek P (1981) Frozen section diagnosis in tumors of the testis. Possibilities limitations indications. Pathol Res Pract 173: 54–65PubMedGoogle Scholar
  50. Hernes EH, Harstad K, Fossa (1996) Changing incidence and delay of testicular cancer in southern Norway (1981–1992). Eur Urol 30: 349–57PubMedGoogle Scholar
  51. Herr HW, Sheinfeld J (1997) Is biopsy of the contralateral testis necessary in patients with germ cell tumors? J Urol 158: 1331–1334PubMedCrossRefGoogle Scholar
  52. Hoei-Hansen CE, Holm M, Rajpert-De Meyts E, Skakkebaek NE (2003) Histological evidence of testicular dysgenesis in contralateral biopsies from 218 patients with testicular germ cell cancer. J Pathol 200: 370–374PubMedCrossRefGoogle Scholar
  53. Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G, Skakkebaek NE (2005) Carcinoma in situ testis the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol 16: 863–868PubMedCrossRefGoogle Scholar
  54. Höppner W, Reinel D, Hartmann M (1986) Examination of the fertility of patients with malignant testicular cancer at the time of orchiectomy. The question of the opinion on cryopreservation. Andrologia 18: 398–405PubMedCrossRefGoogle Scholar
  55. Huddart RA, Norman A, Moynihan C, Horwich A, Parker C, Nicholls E, Dearnaley DP (2005) Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 93: 200–207PubMedCrossRefGoogle Scholar
  56. Huyghe E, Matsuda T, Daudin M, Chevreau C, Bachaud JM, Plante P, Bujan L, Thonneau P (2004) Fertility after testicular cancer treatments: results of a large multicenter study. Cancer 100: 732–737PubMedCrossRefGoogle Scholar
  57. Huyghe E, Muller A, Mieusset R, Bujan L, Bachaud JM, Chevreau C, Plante P, Thonneau P (2007) Impact of diagnostic delay in testis cancer: Results of a large population based study. Eur Urol 52: 1710–1716PubMedCrossRefGoogle Scholar
  58. Huyghe E, Soulie M, Escourrou G, Mieusset R, Plante P, Thonneau P (2005) Conservative management of small testicular tumors relative to carcinoma in situ prevalence. J Urol 173: 820–823PubMedCrossRefGoogle Scholar
  59. Incrocci L, Bosch JL, Slob AK (1999) Testicular prostheses: body image and sexual functioning. BJU Int 84: 1043–1045PubMedCrossRefGoogle Scholar
  60. Johnson DE, Babaian RJ (1980) The case for conservative surgical management of the ilioinguinal region after inadequate orchiectomy. J Urol 123: 44–46PubMedGoogle Scholar
  61. Kazem I, Danella JF (1999) Organ preservation for the treatment of contralateral testicular seminoma. Radiother Oncol 53: 45–47PubMedCrossRefGoogle Scholar
  62. Kliesch S (2004) Fertilität bei Patienten mit Hodenerkrankungen. Onkologe 9: 955–961CrossRefGoogle Scholar
  63. Kliesch S (2004) Diagnostik und Primärtherapie des Hodentumors. Urologe A 43: 1494–1499PubMedCrossRefGoogle Scholar
  64. Kliesch S, Kamischke A, Nieschlag E (2000) Kryokonservierung menschlicher Spermien zur Zeugungsreserve. In: Nieschlag E Behre HM (Hrsg) Andrologie. Grundlagen und Klinik der reproduktiven Gesundheit des Mannes. Springer Berlin Heidelberg New York S 407–416Google Scholar
  65. Kliesch S, Thomaidis T, Schütte B, Puhse G, Kater B, Roth S, Bergmann M (2003) Update on the diagnostic safety for detection of testicular intraepithelial neoplasia (TIN) APMIS 111: 70–74PubMedCrossRefGoogle Scholar
  66. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De, Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså SD, Garcia Del Muro X, Gauler T, Geczi A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Leiva Galvis O, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Paz Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H (2008) European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. Eur Urol 53: 478–496PubMedCrossRefGoogle Scholar
  67. Krege S, Schmoll HJ, Souchon R (2001) Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren. Ergebnisse einer Update-Konferenz auf Grundlage evidenzbasierter Medizin (EBM). Urologe A 40: 137–147PubMedCrossRefGoogle Scholar
  68. Krupienski M, Sparwasser C, Loy V, Kraft K, Pust RA (1997) Die Problematik des diagnostischen und therapeutischen Vorgehens bei einem Patienten mit retroperitonealem Keimzelltumor. [Problems in diagnosis and therapy planning in a patient with retroperitoneal yolk sac tumor. Case report and review of the literature]. Urologe A 36: 557–560PubMedCrossRefGoogle Scholar
  69. Lambert SM, Fisch H (2007) Infertility and testis cancer. Urol Clin North Am 34: 269–277PubMedCrossRefGoogle Scholar
  70. Lampe H, Horwich A, Norman A, Nicholls J, Dearnaley DP (1997) Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 15: 239–245PubMedGoogle Scholar
  71. Leeuwen FEv, Stiggelbout AM, Belt-Dousebout AWvd, Noyon R, Eliel MR, Kerkhoff EHMv, Delemarre JFM, Somers R (1993) Second cancer risk following testicular cancer: A follow-up study of 1909 patients. J clin Oncol 11: 415–424PubMedGoogle Scholar
  72. Leibovitch I, Baniel J, Foster RS, Donohue JP (1995) The clinical implications of procedural deviations during orchiectomy for nonseminomatous testis cancer. J Urol 154: 935–939PubMedCrossRefGoogle Scholar
  73. Leibovitch I, Little JSJ, Foster RS, Rowland RG, Bihrle R, Donohue JP (1996) Delayed orchiectomy after chemotherapy for metastatic nonseminomatous germ cell tumors. J Urol 155: 952–954PubMedCrossRefGoogle Scholar
  74. Leroy X, Rigot JM, Aubert S, Ballereau C, Gosselin B (2003) Value of frozen section examination for the management of nonpalpable incidental testicular tumors. Eur Urol 44: 458–460PubMedCrossRefGoogle Scholar
  75. Lo KC, Wong C, Emond J, Aprikian AG (2001) Scrotal orchiectomy for a large testicular seminoma. Can J Urol 8: 1234–1236PubMedGoogle Scholar
  76. Maase Hvd (2005) Is a contralateral testicular biopsy in patients with unilateral germ cell testicular cancer indicated as a routine procedure? Acta Oncol 44: 523–525PubMedCrossRefGoogle Scholar
  77. Maase vdH, Giwercman A, Müller J, Skakkebaek NE (1987) Management of carcinoma-in-situ of the testis. Int J Androl 10: 209–220PubMedCrossRefGoogle Scholar
  78. Magelssen H, Haugen TB, von During V, Melve KK, Sandstad B, Fossa SD (2005) Twenty years experience with semen cryopreservation in testicular cancer patients: who needs it? Eur Urol 48: 779–785PubMedCrossRefGoogle Scholar
  79. Markland C, Kedia K, Fraley EE (1973) Inadequate orchiectomy for patients with testicular tumors. JAMA 224: 1025–1026PubMedCrossRefGoogle Scholar
  80. Mikuz G (2008) Hodentumoren — prognostische Faktoren. Pathologe 29 (Suppl. 2): 270–272PubMedCrossRefGoogle Scholar
  81. Mottet N, Petit M, Sous-Comité Organes génitaux externes CdCdIA (2004) Conservative surgery for testicular tumours [Article in French]. Prog Urol 14: 15–18PubMedGoogle Scholar
  82. Moul JW (2007) Timely diagnosis of testicular cancer. Urol Clin North Am 34: 109–117PubMedCrossRefGoogle Scholar
  83. Moul JW, Paulson DF, Dodge RK, Walther PJ (1990) Delay in diagnosis and survival in testicular cancer: Impact of effective therapy and and changes during 18 years. J Urol 143: 520–523PubMedGoogle Scholar
  84. Nikzas D, Champion AE, Fox M (1990) Germ cell tumours of testis: prognostic factors and results. Eur Urol 18: 242–7PubMedGoogle Scholar
  85. Osterlind A, Berthelsen JG, Abildgaard N, Hansen SO, Hjalgrim H, Johansen B, Munck Hansen J, Rasmussen LH (1991) Risk of bilateral testicular germ cell cancer in Denmark: 1960–1984. J Natl Cancer Inst 83: 1391–5PubMedCrossRefGoogle Scholar
  86. Ozen H, Altug U, Bakkaloglu MA, Remzi D (1988) Significance of scrotal violation in the prognosis of patients with testicular tumours. Br J Urol 62: 267–270PubMedCrossRefGoogle Scholar
  87. Paduch DA (2006) Testicular cancer and male infertility. Curr Opin Urol 16: 419–427PubMedCrossRefGoogle Scholar
  88. Pont J, Höltl W (2005) Keimzelltumoren des Mannes. Uni Med Verlag: BremenGoogle Scholar
  89. Prym C, Lauke H (1994) Carcinoma-in-situ of the human testis: Tumour cells are distributed focally in the seminiferous tubules. Andrologia 26: 231–234PubMedCrossRefGoogle Scholar
  90. Prym P (1927) Spontanheilung eines bösartigen wahrscheinlich chorionepitheliomatösen Gewächses im Hoden. Virchows Arch Pathol Anat 265: 239–258CrossRefGoogle Scholar
  91. Ramani VA, Grey BR, Addla SK, Dunham MP, Sangar VK, Clarke NW (2008) Histological Outcome of Delayed Orchidectomy after Primary Chemotherapy for Metastatic Germ cell Tumour of the Testis. Clin Oncol (R Coll Radiol) 20: 247–252Google Scholar
  92. Richie JP (1984) Simultaneous bilateral tumors with unorthodox management. World J Urol 2: 74Google Scholar
  93. Schmidt KL, Carlsen E, Andersen AN (2007) Fertility treatment in male cancer survivors. Int J Androl 30: 413–418PubMedCrossRefGoogle Scholar
  94. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C et al. (2004) European Consensus on Diagnosis and Treatment of Germ Cell Cancer. A Report of the European Germ Cell Cancer Consensus Group (EGCCCG) Ann Oncol 15: 1377–1399PubMedCrossRefGoogle Scholar
  95. Scholz M, Zehender M, Thalmann GN, Borner M, Thoni H, Studer UE (2002) Extragonadal retroperitoneal germ cell tumor: evidence of origin in the testis. Ann Oncol 13: 121–124PubMedCrossRefGoogle Scholar
  96. Seppelt U (1982) Enukleation eines sukzessiven Zweittumors im Resthoden. Therapiewoche 32: 560–563Google Scholar
  97. Sibert L, Rives N, Rey D, MacE B, Grise P (1999) Semen cryopreservation after orchidectomy in men with testicular cancer. BJU Int 84: 1038–1042PubMedCrossRefGoogle Scholar
  98. Spermon JR, Kiemeney LA, Meuleman EJ, Ramos L, Wetzels AM, Witjes JA (2003) Fertility in men with testicular germ cell tumors. Fertil Steril 79 Suppl 3: 1543–1549PubMedCrossRefGoogle Scholar
  99. Steiner H, Höltl L, Maneschg C, Berger AP, Rogatsch H, Bartsch G, Hobisch A (2003) Frozen section analysis-guided organ-sparing approach in testicular tumors: technique, feasibility, and long-term results. Urology 62: 508–513PubMedCrossRefGoogle Scholar
  100. Taksey J, Bissada NK, Chaudhary UB (2003) Fertility after chemotherapy for testicular cancer. Arch Androl 49: 389–395PubMedCrossRefGoogle Scholar
  101. Turek PJ, Master VA, Group, TPS (2004) Safety and effectiveness of a new saline filled testicular prosthesis. J Urol 172: 1427–1430PubMedCrossRefGoogle Scholar
  102. van Casteren NJ, Boellaard WP, Dohle GR, Weber RF, Kuizinga MC, Stoop H, Oosterhuis WJ, Looijenga LH (2008) Heterogeneous distribution of ITGCNU in an adult testis: consequences for biopsybased diagnosis. Int J Surg Pathol 16: 21–24PubMedCrossRefGoogle Scholar
  103. Von der Maase H (2005) Is a contralateral testicular biopsy in patients with unilateral germ cell testicular cancer indicated as a routine procedure? Acta Oncol 44: 523–525PubMedCrossRefGoogle Scholar
  104. Von der Maase H, Giwercman A, Müller J, Skakkebaek NE (1987) Management of carcinoma-in-situ of the testis. Int J Androl 10: 209–220PubMedCrossRefGoogle Scholar
  105. Weissbach L (1995) Organ preserving surgery of malignant germ cell tumors. J Urol 153: 90–93PubMedCrossRefGoogle Scholar
  106. Weissbach L (1999) Guidelines for the diagnosis and therapy of testicular cancer and new developments. Urol Int 63: 46–56PubMedCrossRefGoogle Scholar
  107. Weissbach L, Janssen PL, Bach D (1979) Die Implantation von Hodenprothesen unter Berücksichtigung psychischer Aspekte. Urologe A 18: 151–156PubMedGoogle Scholar
  108. Weissbach L, Schaefer C (2008) Organerhaltende Hodentumorchirurgie. Urologe 47: 809–817PubMedCrossRefGoogle Scholar
  109. Winter E, Kliesch S, Souchon R, De Wit M (2005) Diagnostik des Hodentumors. Dtsch Ärztebl 102: A3021–A3025Google Scholar
  110. Wishnow KI, Johnson DE, Preston WL, Tenney DM, Brown BW (1990) Prompt orchiectomy reduces morbidity and mortality from testicular carcinoma. Br J Urol 65: 629–33PubMedCrossRefGoogle Scholar
  111. Wittekind C (2008) Biologie und Pathologie von Keimzelltumoren des Hodens. Onkologe 14: 602–610CrossRefGoogle Scholar
  112. Wittekind C, Loy V (1998) Pathologie und pathologische Diagnostik von Hodentumoren. Onkologe 4: 476–486CrossRefGoogle Scholar
  113. Yossepowitch O, Baniel J (2004) Role of organ-sparing surgery in germ cell tumors of the testis. Urology 63ks: 421–427CrossRefGoogle Scholar

Literatur zu Kap. 26.5

  1. Buchler T, Freeman A, Harland S (2008) Contralateral intratubular germ cell neoplasia in a patient with testicular cancer. Nat Clin Pract Urol 5: 284–288PubMedCrossRefGoogle Scholar
  2. Christensen TB, Daugaard G, Geertsen PF, von der Maase H (1998) Effect of chemotherapy on carcinoma in situ of the testis. Ann Oncol 9: 657–660PubMedCrossRefGoogle Scholar
  3. Classen J, Dieckmann K, Bamberg M, Souchon R, Kliesch S, Kuehn M, Loy V, German Testicular Cancer Study Group (2003) Badiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group. Br J Cancer 88: 828–831PubMedCrossRefGoogle Scholar
  4. Classen J, Dieckmann K-P, Loy V, Bamberg M (1998) Die testikuläre intraepitheliale Neoplasie (TIN) Indikation zur Strahlentherapie? Strahlenther Onkol 174: 173–177PubMedCrossRefGoogle Scholar
  5. Dieckmann KP, Classen J, Souchon R, Loy V (2001) Therapie der testikulären intraepithelialen Neoplasie (TIN) — eine Übersicht auf Grundlage der evidenzbasierten Medizin (EBM). Wien Klin Wochenschr 113: 7–14PubMedGoogle Scholar
  6. Dieckmann KP, Lauke H, Michl U, Winter E, Loy V (2002) Testicular germ cell cancer despite previous local radiotherapy to the testis. Eur Urol 41: 643–649PubMedCrossRefGoogle Scholar
  7. Dieckmann KP, Loy V (1995) Intratesticular effects of cisplatin-based chemotherapy. Eur Urol 28: 25–30PubMedGoogle Scholar
  8. Dieckmann KP, Loy V (1998) The value of the biopsy of the contralateral testis in patients with testicular germ cell cancer: the recent German experience. APMIS 106: 13–20; discussion 20–3PubMedCrossRefGoogle Scholar
  9. Giwercman A, von der Maase H, Berthelsen JG, Rorth M, Bertelsen A, Skakkebaek NE (1991) Localized irradiation of testes with carcinoma in situ: effects on Leydig, cell function and eradication of malignant germ cells in 20 patients. J Clin Endocrinol Metab 73: 596–603PubMedCrossRefGoogle Scholar
  10. Heidenreich A, Beckert R, Vietsch Hv, Engelmann UH (1995) Screening Diagnostik und Therapie der testikulären intraepithelialen Neoplasie (TIN). Akt Urol 26: 175–180CrossRefGoogle Scholar
  11. Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G, Skakkebaek NE (2005) Carcinoma in situ testis the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol 16: 863–868PubMedCrossRefGoogle Scholar
  12. Kliesch S, Bergmann M, Hertle L, Nieschlag E, Behre HM (1997) Semen parameters and testicular pathology in men with testicular cancer and contralateral carcinoma in situ or bilateral testicular malignancies. Hum Reprod 12: 2830–2835PubMedCrossRefGoogle Scholar
  13. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså SD, Garcia Del Muro X, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Leiva Galvis O, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Paz Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H (2008) European Consensus Conference on diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. Eur Urol 53: 478–496PubMedCrossRefGoogle Scholar
  14. Petersen PM, Giwercman A, Daugaard G, Rorth M, Petersen JH, Skakkebaek NE, Hansen SW, von der Maase H (2002) Effect of graded testicular doses of radiotherapy in patients treated for carcinomain-situ in the testis. J Clin Oncol 20: 1537–1543PubMedCrossRefGoogle Scholar
  15. Schmidt KL, Carlsen E, Andersen AN (2007) Fertility treatment in male cancer survivors. Int J Androl 30: 413–418PubMedCrossRefGoogle Scholar
  16. Schmoll HJ, Souchon R, Krege S, Albers P, Beyet J, Kollmannsberger C et al. (2004) European Consensus on Diagnosis and Treamtent of Germ Cell Cancer A Report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15: 1377–1399PubMedCrossRefGoogle Scholar
  17. Skakkebaek NE (2004) Testicular dysgenesis syndrome: New epidemiological evidence. Int J Androl 27: 189–191PubMedCrossRefGoogle Scholar
  18. Souchon R, Gertenbach U, Dieckmann KP, Hahn E, Ruwe M, Stambolis C, Loy V, Classen J (2006) Contralateral testicular cancer inspite of TIN-Negative double biopsies and interval cisplatin chemotherapy. Strahlenther Onkol 182: 289–292PubMedCrossRefGoogle Scholar

Literatur zu Kap. 26.6

  1. Ackers C, Rustin GJ (2006) Lactate dehydrogenase is not a useful marker for relapse in patients on surveillance for stage I germ cell tumours. Br J Cancer 94: 1231–1232PubMedCrossRefGoogle Scholar
  2. Albers P, Bender H, Yilmaz H et al. (1999) Positron emission tomography in the clinical staging of patients with stage I and II germ cell tumors. Urology 53: 808–811PubMedCrossRefGoogle Scholar
  3. Aparicio J, Garcia del Muro X, Maroto P, Paz-Ares L, Alba E, Saenz A, Terrase J, Barnadas A, Almenar D, Arranz JA, Sanchez M, Fernandez A, Sastre J, Carles J, Dorca J, Guma J, Yuste AL, Germa JR; Spanish Germ Cell Cancer Cooperative Group (GG) (2003) Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 14: 867–872PubMedCrossRefGoogle Scholar
  4. Aparicio J, Germa JR, Del Muro XG, Maroto P, Arranz JA, Saenz A, Barnadas A, Dorca J, Guma J, Olmos D, Bastus R, Carles J, Almenar D, Sanchez M, Paz-Ares L, Satrustegui JJ, Mellado B, Balil A, Lopez-Brea M, Sanchez A (2005) Risk-adapted management for patients with clinical stage I seminoma: The Second Spanish Germ Cell Cancer Cooperative Group Study. J Clin Oncol 23: 817–823CrossRefGoogle Scholar
  5. Bamberg M, Schmidberger H, Meisner C et al. (1999) Radiotherapy for stage I, IlA/B testicular seminoma. Int J Cancer 83: 823–827PubMedCrossRefGoogle Scholar
  6. Baniel J, Foster RS, Gonin R et al. (1995) Late relapse of testicular cancer. J Clin Oncol 13: 1170–1176PubMedGoogle Scholar
  7. Barth V, Hums R (1990) Serumhormone und Spermiogrammveränderungen bei Patienten mit malignen Hodentumoren nach Strahlen-und Zytostatikatherapie. Z Urol Nephrol 83: 291–295PubMedGoogle Scholar
  8. Borski A (1973) Diagnosis, staging and natural history of testicular seminoma. Cancer 32: 1202–1206PubMedCrossRefGoogle Scholar
  9. Brenner DJ, Hall EJ (2007) Computed tomography — an increasing source of radiation exposure. N Engl J Med 357: 2277–2284PubMedCrossRefGoogle Scholar
  10. Busch FM, Sayegh ES, Shenault OW Jr. (1965) Some uses of lymphangiography in the management of testicular tumors. J Urol 93: 490–495PubMedGoogle Scholar
  11. Cabot H, Berkson J (1939) Neoplasms of the testis: a study of the results of orchidectomy, with and without irradiation. New Engl J Med 220: 192–195CrossRefGoogle Scholar
  12. Capelouto CC, Clark PE, Ransil BJ et al. (1995) A review of scrotal violation in testicular cancer: Is adjuvant local therapy necessary? J Urol 153: 981–985PubMedCrossRefGoogle Scholar
  13. Chaganti RSK, Houldsworth J (2000) Genetics and biology of adult human germ cell tumors. Cancer Res 60: 1475–1482PubMedGoogle Scholar
  14. Choo R, Thomas G, Woo T, Lee D, Kong B, Iscoe N, Danjoux C, Klotz L, Morton G, Chander S (2005) Long-term outcome of postorchiectomy surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys 61: 736–740PubMedGoogle Scholar
  15. Classen J, Schmidberger H, Meisner C, Winkler C, Dunst J, Souchon R, Weissbach L, Budach V, Alberti W, Bamberg M (2004) Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG). Br J Cancer 90: 2305–2311PubMedGoogle Scholar
  16. Classen J, Souchon R, Lächelt S et al. (2006) Follow-up strategies after paraaortic (PA) radiotherapy for stage I seminoma: What should we do and when should we do it? 27. Deutscher Krebskongress. 22.–26.03.2006, Berlin, Abstract-Nr: PO294. www.krebskongress2006.deGoogle Scholar
  17. Dahl AA, Mykletun A, Fossa SD (2005) Quality of life in surviors of testicular cancer. Urol Oncol 23: 193–200PubMedGoogle Scholar
  18. Daugaard G, Petersen PM, Rorth M (2003) Surveillance in stage I testicular cancer. APMIS 111: 76–83PubMedCrossRefGoogle Scholar
  19. De Giorgi U, Tana S, Rosti G et al. (2006) Follow-up strategy of germ cell tumour patients. Ann Oncol 17: 529–U4PubMedCrossRefGoogle Scholar
  20. Deutsche Krebsgesellschaft e.V. (2002) Qualitätssicherung in der Onkologie — Leitlinie zur Diagnostik und Therapie von Hodentumoren auf der Grundlage evidenzbasierter Medizin (EBM). In: Souchon R, Schmoll H-J, Krege S (Hrsg) Zuckschwerdt, MünchenGoogle Scholar
  21. Dieckmann KP, Krain J, Küster J et al. (1996) Adjuvant carboplatin treatment for seminoma clinical stage. J Cancer Res Clin Oncol 122: 63–66PubMedCrossRefGoogle Scholar
  22. Dieckmann KP, Pichlmeir U (1997) The prevalence of familial testicular cancer. Cancer 80: 1954–1960PubMedCrossRefGoogle Scholar
  23. Dieckmann KP, Brüggeboes B, Pichlmeier U et al. (2000) Adjuvant treatment of clinical stage I seminoma: Is one single course of carboplatin sufficient? Urology 55: 102–106PubMedCrossRefGoogle Scholar
  24. Donovan PJ (1998) The germ cell — the mother of all stem cells. Int J Dev Biol 42: 1043–1050PubMedGoogle Scholar
  25. Erpenback K, Derschum W, Reis M (1997) Ergebnisse einer engmaschigen Hodentumornachsorge. Urologe A 29: 102–7Google Scholar
  26. Ferlay J, Bray F, Pisani P et al. (2001) GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0 IARC Cancer Base No. 5. Lyon: IARC 2001 (auch: www.iarc.fr/globocan/database.pdf)Google Scholar
  27. Fitzgerald R, Twiss D, Mehra R, Evans M, Qaiyum M, Collins M (2004) Low-dose computed tomography surveillance of patients with testicular tumours. Clin Oncol (R Coll Radiol) 16: 158Google Scholar
  28. Forman D, Oliver RTD, Marsh SGE et al. (1992) Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis. Brit J Cancer 65: 255–262PubMedGoogle Scholar
  29. Fossa SD, Abyholm T, Vespestad S et al. (1993) Semen quality after treatment for testicular cancer. Eur Urol 23: 172–176PubMedGoogle Scholar
  30. Fossa SD, Horwich A, Russel JM et al. (1999) Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. J Clin Oncol 117: 1146–1154Google Scholar
  31. Fossa SD, Aass N, Winderen M, Bormer OP, Olsen DR (2002) Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol 13: 222–228PubMedCrossRefGoogle Scholar
  32. Fossa SD, Gilbert E, Dores GM et al. (2007) Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 99: 533–544PubMedCrossRefGoogle Scholar
  33. Fossa SD, Johannesen TB, Lehne G (2006) Long-term outcome after adult-onset cancer. Ann Oncol 17 Suppl 10: X292–98Google Scholar
  34. Francis R, Bower M, Brunstrom G, Holden L, Newlands ES, Rustin GJ, Seckl MJ (2000) Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur J Cancer 36: 1925–1932PubMedCrossRefGoogle Scholar
  35. Gatta G, Ciccolallo L, Kunkler I et al. EUROCARE Working Group (2006). Survival from rare cancer in adults: a population-based study. Lancet Oncol 7: 132–140PubMedCrossRefGoogle Scholar
  36. Germa-Lluch JR, Climent MA, Villavicencio H et al. (1993) Br J Urol 71: 473–477PubMedCrossRefGoogle Scholar
  37. Gray A, Guillou L, Zufferey J et al. (1998) Persistence of parvovirus B19 DNA in testis of patients with testicular germ cell tumours. J Gen Virol 79: 573–579PubMedGoogle Scholar
  38. Hentrich M, Meiler S, Fegg M, Gerl A (2008) Changes in sexual functioning after germ cell tumor (GCT) therapy estimated by patients and their partners. J Clin Oncol 26: May 20 suppl; abstr 5086Google Scholar
  39. Herbst H, Sauter M, Mueller-Lantzsch N (1996) Expression of human endogeneous retrovirus K elements in germ cell and trophoblastic tumours. Am J Pathol 149: 1727–1735PubMedGoogle Scholar
  40. Hilton S, Herr HW, Teitcher JB, Begg CB, Castellino RA (1997) CT detection of retropertioneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. Am J Roentgenol 169: 521–525Google Scholar
  41. Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G et al. (2005) Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol 16: 863–868PubMedCrossRefGoogle Scholar
  42. Horwich A, Alsanjari N, A’Hern R, Nicholls J, Dearnaley DP, Fisher C (1992) Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 65: 775–778PubMedGoogle Scholar
  43. Horwich A, Dearnaley D, Hern RA et al. (1992) Activity of single agent Carboplatin in advanced seminoma. Eur J Cancer 28-A: 1307–1310CrossRefGoogle Scholar
  44. Horwich A (2004) Radiotherapy in stage I seminoma of the testis. J Clin Oncol 22: 585–588PubMedCrossRefGoogle Scholar
  45. Horwich A, Shipley J, Huddart R (2006) Testicular germ-cell cancer. Lancet 367(9512): 754–65PubMedCrossRefGoogle Scholar
  46. Huddart R, Kataja V (2008) ESMO Guidelines Working Group. Testicular seminoma: ESMO cilinical recommendations for diagnosis, treatment and follow-up. Ann Oncol: 19Suppl 2:ii49–51PubMedCrossRefGoogle Scholar
  47. Huyghe E, Matsuda T, Thonneau P (2003) Increasing incidence of testicular cancer worldwide: a review. J Urol 170: 5–11PubMedCrossRefGoogle Scholar
  48. Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A, Stenning SP (2005) Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 23: 1200–1208PubMedCrossRefGoogle Scholar
  49. Joos H, Sedlmayer F, Gomahr A et al. (1997) Endokrine profiles after radiotherapy in stage I seminoma: impact of two different radiation treatment modalities. Radiother Oncol 43: 159–162PubMedCrossRefGoogle Scholar
  50. Krege S, Kalund G, Otto T et al. (1997) Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Eur Urol 31: 405–407PubMedGoogle Scholar
  51. Krege S, Beyer J, Souchon R et al. (2008a) European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. Eur Urol 53: 478–496PubMedCrossRefGoogle Scholar
  52. Krege S, Beyer J, Souchon R et al. (2008b) European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. Eur Urol 53: 497–513PubMedCrossRefGoogle Scholar
  53. Krug B (1997) Becken. In: Heindel W, Kugel H, Lackner K (Hrsg) Rationelle MR-Untersuchungstechniken. Thieme, Stuttgart, pp 52–55Google Scholar
  54. Krug B, Heidenreich A, Dietlein M et al. (1999) Lymphknotenstaging maligner testikulärer Keimzelltumoren. Fortschr Röntgenstr 171: 87–94CrossRefGoogle Scholar
  55. Lashley D, Lowe B (1998) A rational approach to managing stage I non-seminomatous germ cell cancer. Urol Clin North Am 25: 405–423PubMedCrossRefGoogle Scholar
  56. Lassen U, Daugaard G, Eigtved A et al. (2003) Wholebody positron emission tomography (PET) with FDG in patients with stage I non-seminomatous germ cell tumours (NSGCT). Eur J Nucl Med Imaging 30: 396–402Google Scholar
  57. Leibovitch I, Foster RS, Kopecky KK et al. (1995) Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell tumor using size criteria of retroperitoneal lymph nodes. J Urol 154: 1759–1763PubMedCrossRefGoogle Scholar
  58. Leibovitch I, Foster RS, Kopecky KK et al. (1998) Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: A combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment. J Clin Oncol 16: 261–268PubMedGoogle Scholar
  59. Linke J, Loy V, Dieckmann KP (2005) Prevalence of testicular intraepithelial neoplasia in healthy males. J Urol 173: 1577–1579PubMedCrossRefGoogle Scholar
  60. Loehrer PJ Sr, Bosl GJ (2005) Carboplatin for stage I seminoma and the sword of damocles. J Clin Oncol 24: 467–475Google Scholar
  61. Logue JP, Harris MA, Livsey JE, Swindell R, Mobarek N, Read G (2003) Short course para-aortic radiation for stage I seminoma of the testis. Int J Radiat Oncol Biol Phys 57: 1304–1309PubMedGoogle Scholar
  62. Looijenga LH, Hersmus R, Gillis AJ, Pfundt R, Stoop HJ, van Gurp RJ, Veltman J, Beverloo HB, van Drunen E, van Kessel AG, Pera RR, Schneider DT, Summersgill B, Shipley J, McIntyre A, van der Spek P, Schoenmakers E, Oosterhuis JW (2006) Genomic and expression profiling of human spermatocytic seminomas: primary spermatocyte as tumorigenic precursor and DMRT1 as candidate chromosome 9 gene. Cancer Res 66: 290–302PubMedCrossRefGoogle Scholar
  63. Looijenga LHJ, Stoop H, Hersmus R, Gillis AJM, Oosterhuis JW (2007) Genomic and expression profiling of human spermatocytic seminomas: pathogenetic implications. Int J Androl 30: 328–336PubMedCrossRefGoogle Scholar
  64. Majewski W, Majewski S, Maciejewski A, Kolosza Z, Tarnawski R (2005) Adverse effects after radiotherapy for early stage (I, IIa, IIb) seminoma. Radiother Oncol 2;76: 257–63CrossRefGoogle Scholar
  65. Mason MD, Featherstone T, Olliff J, Horwich A (1991) Inguinal and iliacal lymph node involvement in germ cell tumours of the testis: Implications for radiological investigation and for therapy. Clin Oncol 3: 147–150CrossRefGoogle Scholar
  66. Mason M, Jones W (1997) Treatment of stage I seminoma: more choice, more dilemmas. Clin Oncol 9: 210–212CrossRefGoogle Scholar
  67. McGlynn KA, Devesa SS, Sigurdson AJ, Brown LM, Tsao L, Tarone RE (2003) Trends in the incidence of testicular germ cell tumors in the United States. Cancer 97: 63–70PubMedCrossRefGoogle Scholar
  68. McGlynn KA, Devesa SS, Graubard BI, Castle PE (2005) Increasing incidence of testicular germ cell tumors among black men in the United States. J Clin Oncol 23: 5757–5761PubMedCrossRefGoogle Scholar
  69. Mead GM, Fosså SD, Oliver RT, Fogarty PJ, Pollock P, Stenning SP, MRC and EORTC trial collaborators (2008) Relapse patterns in 2,466 stage 1 seminoma patients (pts) entered into Medical Research Council randomised trials. J Clin Oncol 20, suppl, abstr 5020Google Scholar
  70. Moller H, Prener A, Skakkebaek NE (1996) Testicular cancer, cryptorchidism, inguinal hernia, testicular atrophy and genital malformations: case-control studies in Denmark. Cancer Causes Control 7: 264–274PubMedCrossRefGoogle Scholar
  71. Mostofi FK, Sesterhenn IA (1998) Histological typing of testis tumours. WHO International Histological Classification of Tumours. 2nd ed. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  72. Mottet N, Rousmans S, Culine S (2008) Systematic review 2007: Primary treatments of testicular germ cell tumors after radical orchydectomy. Bull Cancer 95: 205–234PubMedGoogle Scholar
  73. Nathan PD, Rustin GR (2003) The role of CT scanning in the surveillance of testicular tumours. Clin Oncol (R Coll Radiol) 15: 121–122Google Scholar
  74. Oldenburg J, Martin JM, Fosså SD (2006) Late relapses of germ cell malignancies: incidence, management, and prognosis. J Clin Oncol 24: 5503–5511PubMedCrossRefGoogle Scholar
  75. Oliver RTD, Lore SH, Ong J (1990) Alternatives to radiotherapy in the management of seminoma. Br J Urol 65: 61–67PubMedCrossRefGoogle Scholar
  76. Oliver RTD, Edmonds PM, Ong J et al. (1994) Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy? Int J Radiat Oncol Biol Phys 29: 3–8PubMedGoogle Scholar
  77. Oliver RTD, Boublikova L, Ong J (2001) Fifteen year follow up of the anglian germ cell cancer group adjuvant studies of carboplatin as an alternativ to radiation or surveillance for stage 1 seminoma. Proc Am Soc Clin Oncol 20: 196a. Abstract #780Google Scholar
  78. Oliver T, Dieckmann K-P, Steiner H, Skoneczna I (2005a) Pooled analysis of phase 2 reports of 2 v 1 course of carboplatin as adjuvant for stage 1 seminoma. J Clin Oncol 23, No 16S, Part I: 395s Abstract #4572Google Scholar
  79. Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, De Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP; MRC TE 19 collaborators and the EORTC 30982 collaborators (2005b) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366: 293–300PubMedCrossRefGoogle Scholar
  80. Oliver RT, Mead GM, Fogarty PJ, Stenning SP, MRC TE19 and EORTC 30982 trial collaborators (2008) Radiotherapy versus carboplatin for stage I seminoma: Updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214). J Clin Oncol 26: 20 suppl, abstr 1CrossRefGoogle Scholar
  81. Osterlind A, Berthelsen JG, Abilgaard N et al. (1991) Risk of bilateral testicular germ cell tumors in Denmark: 1960–1984. J Natl Cancer Inst 83: 1391–1395PubMedCrossRefGoogle Scholar
  82. Oxford Centre for Evidence based Medicine (2001) Levels of evidence. http://minerva.minervation.com/cebm/Google Scholar
  83. Petersen PM, Giwercman A, Skakkebaek NE, Rorth M (1998) Gonadal function in men with testicular cancer. Semin Oncol 25: 224–233PubMedGoogle Scholar
  84. Pinczowski D, McLaughlin JK, Lackgren G, Adami HO, Persson I (1991) Occurrence of testicular cancer in patients operated on for cryptorchidism and inguinal hernia. J Urol 146: 1291–1294PubMedGoogle Scholar
  85. Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T (2008) The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 9: 443–447Google Scholar
  86. Prener A, Hsieh CC, Engholm G, Christophersen IS, Hald T, Jacobsen GK, Berthelsen JG, Skakkebaek NE (1992) Birth order and risk of testicular cancer. Cancer Causes Control 3: 265–272PubMedCrossRefGoogle Scholar
  87. Purdue MP, Devesa SS, Sigurdson AJ, McGlynn KA (2005) International patterns and trends in testis cancer incidence. Int J Cancer 115: 822–827PubMedCrossRefGoogle Scholar
  88. Ramakrishnan S, Champion AE, Dorreen MS, Fox M (1992) Stage I seminoma of the testis: is post-orchidectomy surveillance a safe alternative to routine postoperative radiotherapy? Clin Oncol (R Coll Radiol) 4: 284–286Google Scholar
  89. Ray B, Hajdu SI, Whitmore WF (1974) Distribution of retroperitoneal lymph node metastases in germinal tumors. Cancer 33: 340–348PubMedCrossRefGoogle Scholar
  90. Reiter WJ, Brodowicz T, Alavi S, Zielinski CC, Kozak W, Maier U, Nöst G, Lipsky H, Marberger M, Kratzik C (2001) Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol 19: 101–104PubMedGoogle Scholar
  91. Roelofs H, Mostert M, Pompe K et al. (2000) Restricted 12p amplification and ras mutation in human germ cell tumors of the adult testis. Am J Pathol 157: 1155–1166PubMedGoogle Scholar
  92. Rüther U, Dieckmann K, Bussar-Maatz R, Eisenberger F (2000) Second malignancies following pure seminoma. Oncology 58: 75–82PubMedCrossRefGoogle Scholar
  93. Schairer C, Hisada M, Chen BE, Brown LM, Howard R, Fosså SD, Gail M, Travis LB (2007) Comparative mortality for 621 second cancers in 29356 testicular cancer survivors and 12420 matched first cancers. J Natl Cancer Inst 99: 1248–1256PubMedCrossRefGoogle Scholar
  94. Schmidberger H, Bamberg M (1995) Therapieoptionen bei testikulären Seminomen in den frühen Stadien. Strahlenther Onkol 171: 125–139PubMedGoogle Scholar
  95. Schmidberger H, Virsik-Koepp P, Rave-Frank M, Reinosch KR, Pradier O, Munzel U, Hess CF (2001) Reciprocal translocations in patients with testicular seminoma before and after radiotherapy. Int J Radiat Oncol Biol Phys 50: 857–864PubMedCrossRefGoogle Scholar
  96. Schmoll HJ, Harstrick A, Bokemeyer C, Dieckmann KP, Clemm Ch, Berdel W, Souchon R, Schöber Ch, Wilke H, Poliwoda H (1993) Single agent carboplatinum for advanced seminoma: a phase II study. Cancer 72: 237–243PubMedCrossRefGoogle Scholar
  97. Schmoll HJ, Souchon R, Krege S et al. (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15: 1377–1399PubMedCrossRefGoogle Scholar
  98. Skakkebaek NE (1972) Possible carcinoma-in-situ of the testis. Lancet 2(7776): 516–517PubMedCrossRefGoogle Scholar
  99. Sobin LH, Wittekind Ch (eds) (2002) UICC: TNM classification of malignant tumours, 6th edn. Wiley-Liss, New YorkGoogle Scholar
  100. Souchon R, Krege S, Schmoll HJ, Albers P, Beyer J, Bokemeyer C, Claßen J, Diekmann KP, Hartmann M, Heidenreich A, Höltl W, Kliesch S, Köhrmann KU, Kuczyk M, Schmidberger H, Weinknecht S, Winter E, Wittekind C, Bamberg M für die German Testicular Cancer Study Group (GTCSG) (2000) Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren: Ergebnisse einer Update-Konferenz auf Grundlage evidenzbasierter Medizin (EBM). Strahlenther Onkol 176: 388–405PubMedCrossRefGoogle Scholar
  101. Spermon JR, De Geus-Oei LF, Kiemeney LA, Witjes JA, Oyen WJ (2002) The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. Brit J Urol Int 89: 549–556Google Scholar
  102. Statistisches Landesamt Saarland (2002) Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland. Krebs in Deutschland, Häufigkeiten und Trends. 3. erweiterte aktualisierte Auflage. SaarbrückenGoogle Scholar
  103. Steiner H, Höltl L, Wirtenberger W, Berger AP, Bartsch G, Hobisch A (2002) Long-term experience with carboplatin monotherapy for clinical stage I seminoma: a retrospective single-center study. Urology 60: 324–328PubMedCrossRefGoogle Scholar
  104. Swerdlow AJ, De Stavola BL, Swanwick MA, Mangtani P, Maconochie NE (1999) Risk factor for testicular cancer: a case control study in twins. Br J Cancer 80: 1098–1102PubMedCrossRefGoogle Scholar
  105. Thomas GM (1993) Surveillance in stage I seminoma of the testis. Urol Clin North Am 20: 85–91PubMedGoogle Scholar
  106. Thomas GM (1996) Para-aortic radiotherapy for stage I seminoma: a new standard. Int J Radiat Oncol Biol Phys 35: 413–414PubMedGoogle Scholar
  107. Thorsen L, Nystad W, Stigum H, Dahl O, Klepp O, Bremnes RM, Wist E, Fossa SD (2005) The association between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men in a general population sample. Support Care Cancer 13: 637–646PubMedCrossRefGoogle Scholar
  108. Tollerud DJ, Blattner WA, Fraser MC, Brown LM, Pottern L, Shapiro E, Kirkemo A, Shawker TH, Javadpour N, O’Connell K et al. (1985) Familial testicular cancer and urogenital developmental anomalies. Cancer 55: 1849–1854PubMedCrossRefGoogle Scholar
  109. Travis LB, Curtis RE, Storm H et al. (1997) Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89: 1429–1439PubMedCrossRefGoogle Scholar
  110. Travis LB, Fossa SD, Schonfeld SJ et al. (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97: 1354–1365PubMedCrossRefGoogle Scholar
  111. UICC (International Union Against Cancer) (2006) Prognostic factors. In: Gospodarowicz MK, O’Sullivan B, Sobin LH (eds) Cancer. 3rd ed. LavoisierGoogle Scholar
  112. van As NJ, Gilbert DC, Money-Kyrle J, Bloomfield D, Beesley S, Dearnaley DP, Horwich A, Huddart RA (2008) Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br J Cancer 98: 1894–1902PubMedCrossRefGoogle Scholar
  113. van den Belt-Dusebout AW, de Wit R, Gietema JA et al. (2007) Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25: 4370–4378PubMedCrossRefGoogle Scholar
  114. von der Maase H (1999). UICC-Symposium on Testicular Cancer, Tübingen, Abstractband, pp 21–22Google Scholar
  115. von der Maase H, Rorth M, Walbom-Jorgensen S et al. (1986) Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br Med J (Clin Res Ed) 293: 1398–401CrossRefGoogle Scholar
  116. von der Maase H, Specht L, Jacobsen GK et al. (1993) Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer 29A: 1931–1934PubMedCrossRefGoogle Scholar
  117. von der Maase H, Warde P, Specht L et al. (1998) Prognostic factors for relapse following surveillance in seminoma stage I patients. Radiother Oncol 48: Suppl 1: 11, Abstract #42Google Scholar
  118. Warde P, Jewett MAS (1998) Surveillance for stage I testicular seminoma. Is it a good option? Urol Clin North Am 25: 425–433PubMedCrossRefGoogle Scholar
  119. Warde P, Gospodarowicz M (2005) Adjuvant carboplatin in stage I seminoma. Lancet 366: 267–268PubMedCrossRefGoogle Scholar
  120. Warde P, Gospodarowicz MK, Panzarella T et al. (1995) Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 13: 2255–2262PubMedGoogle Scholar
  121. Warde P, Gospodarowicz MK, Banerjee D et al. (1997) Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol 157: 1705–1710PubMedCrossRefGoogle Scholar
  122. Warde P, von der Maase H, Horwich A et al. (1998a) Prognostic factors for relapse in stage I seminoma managed by surveillance. Proc Am Soc Clin Oncol 17: 309a. Abstract #1188Google Scholar
  123. Warde P, Gospodarowicz M, Panzarella T et al. (1998b) Management of stage II seminoma. J Clin Oncol 16: 290–294PubMedGoogle Scholar
  124. Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, von der Maase H (2002) Prognostic factors for relapse in stage I seminoma managed by surveillance. J Clin Oncol 20: 4448–4452PubMedCrossRefGoogle Scholar
  125. Warde PR, Chung P, Sturgeon J, Panzarella T, Giuliani M, Tew-George B, Jewett M, Bayley A, Moore M, Catton C, Gospodarowicz M (2005) Should surveillance be considered the standard of care in stage I seminoma? J Clin Oncol 23: 3825 Part 1 Suppl. S. Abstract #4520Google Scholar
  126. Weissbach L, Boedefeld EA (1987) Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. J Urol 138:77–82PubMedGoogle Scholar
  127. Weissbach L, Bussar-Maatz R, Löhrs U et al. (1999) Prognostic factors in seminomas with special respect to HCG: results of a prospective multicenter study. Seminoma Study Group. Eur Urol 36: 601–608PubMedCrossRefGoogle Scholar
  128. Westergaard T, Olsen JH, Frisch M, Kroman N, Nielsen JW, Melbye M (1996) Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population based study. Int J Cancer 66: 627–631PubMedCrossRefGoogle Scholar
  129. White PM, Howard GC, Best JJ et al. (1997) The role of computed tomographic examination of the pelvis in the management of testicular germ cell tumours. Clin Radiol 52: 124–129PubMedCrossRefGoogle Scholar
  130. Zagars GK, Ballo MT, Lee AK, Strom SS (2004) Mortality after cure of testicular seminoma. J Clin Oncol 22: 640–647PubMedCrossRefGoogle Scholar

Literatur zu Kap. 26.7

  1. Albers P, Bierhoff E, Neu D, Fimmers R, Wernert N, Muller SC (1997) MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis. Cancer 79 (9): 1710–1716PubMedCrossRefGoogle Scholar
  2. Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack HJ, Mueller SC (1999) Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology 53 (4): 808–811PubMedCrossRefGoogle Scholar
  3. Albers P, Siener R, Kliesch S, Weissbach L, Krege S, Sparwasser C, Schulze H, Heidenreich A, de Riese W, Loy V, Bierhoff E, Wittekind C, Fimmers R, Hartmann M (2003) German Testicular Cancer Study Group Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 21: 1505–1512PubMedCrossRefGoogle Scholar
  4. Albers P, Siener R, Krege S, Schmelz H, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Weissbach L, Loy V, Wittekind C, Hartmann M (2008) Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I non-seminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 26 (18): 2966–72PubMedCrossRefGoogle Scholar
  5. Amato RJ, Ro JY, Ayala AG, Swanson DA (2004) Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis. Urology 63: 144–8; discussion 148–149PubMedCrossRefGoogle Scholar
  6. Aparicio J, Germa JR, Garcia del Muro X, Maroto P, Arranz JA, Saenz A, Barnadas A, Dorca J, Guma J, Olmos D, Bastus R, Carles J, Almenar D, Sanchez M, Paz-Ares L, Satrustegui JJ, Mellado B, Balil A, Lopez-Brea M, Sanchez A (2005) The Second Spanish Germ Cell Cancer Cooperative Group. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 23:8717–8723PubMedCrossRefGoogle Scholar
  7. Baniel J, Foster RS, Rowland RG et al. (1994) Complications of primary retroperitoneal lymph node dissection. J Urol 152 (2 Pt 1): 424–427PubMedGoogle Scholar
  8. Bokemeyer C, Schmoll HJ (1993) Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 11 (9): 1703–1709PubMedGoogle Scholar
  9. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ (1996) Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14 (11): 2923–2932PubMedGoogle Scholar
  10. Boyer M, Raghavan D (1992) Toxicity of treatment of germ cell tumors. Semin Oncol 19 (2): 128–142PubMedGoogle Scholar
  11. Chevreau C, Mazerolles C, Soulie M, Gaspard MH, Mourey L, Bujan L, Plante P, Rischmann P, Bachaud JM, Malavaud B (2004) Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol 46:209–214PubMedCrossRefGoogle Scholar
  12. Corti Ortiz D, Foneron Burgos A, Troncoso Schifferli L (1997) Treatment of stage I nonseminomatous testicular cancer with one cycle of adjuvant chemotherapy. Actas Urol Esp 21 (10): 961–963PubMedGoogle Scholar
  13. Cullen MH, Stenning SP, Parkinson MC et al. (1996) Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 14 (4): 1106–1113PubMedGoogle Scholar
  14. De Riese WT, De Riese C, Ulbright TM et al. (1994) Flow-cytometric and quantitative histologic parameters as prognostic indicators for occult retroperitoneal disease in clinical-stage-I non-seminomatous testicular germ-cell tumors. Int J Cancer 57 (5): 628–633PubMedCrossRefGoogle Scholar
  15. Dearnaley DP, Fossa SD, Kaye SB, Cullen MH, Harland SJ, Sokal MP, Graham JD, Roberts JT, Mead GM, Williams MV, Cook PA, Stenning SP (2005) for the MRC Testicular Tumour Working Party. Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective tiral (MRC TE17). Br J Cancer 92: 2107–2113PubMedCrossRefGoogle Scholar
  16. De Wit M, Hartmann J, Kotzerke M, Wirth W, Brenner D, Hellwig J, Lehmann R, Heicappell C, Bokemeyer R, Bares (2005) German Multicenter PET Study Group 18F-FDG-PET in clinical stage I and II non-seminomatous germ cell tumors: first results of the German multicenter trial. J Clin Oncol 23:4504 (supplement)Google Scholar
  17. Donohue JP, Thornhill JA, Foster RS et al. (1993) Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965–1989. Br J Urol 71 (3): 326–35PubMedCrossRefGoogle Scholar
  18. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R (1995) Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965–1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer 31A (10): 1599–1604PubMedCrossRefGoogle Scholar
  19. Duran I, Sturgeon JF, Jewett MA, Anson-Cartwright L, Berthold DR, Kakiashvili D, Warde PR, Alison RE, Pond GR, Moore MJ (2007) Initial versus recent outcomes with a non-risk adapted surveillance policy in stage I non-seminomatous germ cell tumors (NSGCT). J Clin Oncol 25, No 18S: 5021 (abstract)Google Scholar
  20. Fossa SD, Jacobsen AB, Aass N et al. (1994) How safe is surveillance in patients with histologically low-risk non-seminomatous testicular cancer in a geographically extended country with limited computerised tomographic resources? Br J Cancer 70 (6): 1156–1160PubMedGoogle Scholar
  21. Freedman LS, Parkinson MC, Jones WG et al. (1987) Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 2 (8554): 294–298PubMedCrossRefGoogle Scholar
  22. Gels ME, Hoekstra HJ, Sleijfer DT et al. (1995) Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a singlecenter 10-year experience. J Clin Oncol 13 (5): 1188–1194PubMedGoogle Scholar
  23. Hain SF, O’Doherty MJ, Timothy AR, Leslie MD, Partridge SE, Huddart RA (2000) Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med 27 (5): 590–594PubMedCrossRefGoogle Scholar
  24. Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW (1998) Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 83 (5): 1002–1011PubMedCrossRefGoogle Scholar
  25. Heidenreich A, Albers P, Kliesch S et al. (2002) Morbidity of primary nerve-sparing retroperitoneal lymph node dissection in clinical stage I nonseminomatous testis cancer. Journal of Urology 167 (4): 154 (Abstract)CrossRefGoogle Scholar
  26. Hendry WF, Norman A, Nicholls J, Dearnaley DP, Peckham MJ, Horwich A (2000) Abdominal relapse in stage 1 nonseminomatous germ cell tumours of the testis managed by surveillance or with adjuvant chemotherapy. BJU Int 86 (1): 89–93PubMedCrossRefGoogle Scholar
  27. Janetschek G (2001) Laparoscopic retroperitoneal lymph node dissection. Urol Clin North Am 28 (1): 107–114PubMedCrossRefGoogle Scholar
  28. Janetschek G, Hobisch A, Peschel R et al. (2000) Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome. J Urol 163 (6): 1793–6PubMedCrossRefGoogle Scholar
  29. Janetschek G, Peschel R, Hobisch A, Bartsch G (2001) Laparoscopic retroperitoneal lymph node dissection. J Endourol 15 (4): 449–53; discussion 453–455PubMedCrossRefGoogle Scholar
  30. Klepp O, Dahl O, Flodgren P et al. (1997) Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer. Eur J Cancer 33 (7): 1038–1044PubMedCrossRefGoogle Scholar
  31. Kollmannsberger C, Beyer J, Droz JP et al. (1998) Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 16 (10): 3386–3391PubMedGoogle Scholar
  32. Lassen U, Daugaard G, Eigtved A, Hojgaard L, Damgaard K, Rorth M (2003) Whole-body FDG-PET in patients with stage I nonseminomatous germ cell tumours. Eur J Nucl Med Mol Imaging 30:396–402PubMedGoogle Scholar
  33. Leibovitch I, Foster RS, Kopecky KK, Albers P, Ulbright TM, Donohue JP (1998) Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment. J Clin Oncol 16 (1): 261–268PubMedGoogle Scholar
  34. Moul JW, McCarthy WF, Fernandez EB, Sesterhenn IA (1994) Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer. Cancer Res 54 (2): 362–364PubMedGoogle Scholar
  35. Nelson JB, Chen RN, Bishoff JT et al. (1999) Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urol 54 (6): 1064–7PubMedCrossRefGoogle Scholar
  36. Nielsen ME, Lima G, Schaeffer EM, Porter J, Cadeddu JA, Tuerk I, Kavoussi LR (2007) Oncologic efficacy of laparoscopic RPLND in treatment of clinical stage I nonseminomatous germ cell testicular cancer. Urology 70: 1168–72PubMedCrossRefGoogle Scholar
  37. Nuver J, Smit AJ, van der Meer J, van den Berg MP, van der Graaf WT, Meinardi MT, Sleijfer DT, Hoekstra HJ, van Gessel Al, van Roon AM, Gietema JA (2005) Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 23:9130–9137PubMedCrossRefGoogle Scholar
  38. Oliver RT, Raja MA, Ong J, Gallagher CJ (1992) Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage 1 malignant teratoma on overall relapse rate of stage 1 cancer patients. J Urol 148: 1453–5; discussion 1455–1456PubMedGoogle Scholar
  39. Oliver RT, Ong J, Shamash J, Ravi R, Nagund V, Harper P, Ostrowski MJ, Sizer B, Levay J, Robinson A, Neal DE, Williams M (2004) for the Anglian Germ Cell Cancer Group. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with stage I nonseminoma treated with adjuvant chemotherapy. Urol 63:556–561PubMedCrossRefGoogle Scholar
  40. Ondrus D, Matoska J, Belan V, Kausitz J, Goncalves F, Hornak M (1998) Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment. Eur Urol 33 (6): 562–566PubMedCrossRefGoogle Scholar
  41. Pectasides D, Skarlos D, Dimopoulos AM, Farmakis D, Pectasides M, Fountzilas G, Aravantinos G (2003) Two cycles of carboplatinbased adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial. Anticancer Res 23: 4239–4244PubMedGoogle Scholar
  42. Pont J, Albrecht W, Postner G, Sellner F, Angel K, Holtl W (1996) Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 14 (2): 441–448PubMedGoogle Scholar
  43. Rassweiler JJ, Frede T, Lenz E et al. (2000) Long-term experience with laparoscopic retroperitoneal lymph node dissection in the management of low-stage testis cancer. Eur Urol 37 (3): 251–260PubMedCrossRefGoogle Scholar
  44. Read G, Stenning SP, Cullen MH et al. (1992) Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 10 (11): 1762–1768PubMedGoogle Scholar
  45. Schefer H, Mattmann S, Borner M et al. (2000) Single course adjuvant bleomycin, etoposide and cisplatin (BEP) for high risk stage I nonseminomatous germ cell tumors (NSGCT). Proc ASCO 19: 340aGoogle Scholar
  46. Sharir S, Jewett MA, Sturgeon JF et al. (1999) Progression detection of stage I nonseminomatous testis cancer on surveillance: implications for the followup protocol. J Urol 161 (2): 472–475; discussion 475–476PubMedCrossRefGoogle Scholar
  47. Sogani PC, Perrotti M, Herr HW, Fair WR, Thaler HT, Bosl G (1998) Clinical stage I testis cancer: long-term outcome of patients on surveillance [see comments]. J Urol 159 (3): 855–858PubMedCrossRefGoogle Scholar
  48. Studer UE, Burkhard FC, Sonntag RW (2000) Risk adapted management with adjuvant chemotherapy in patients with high risk clinical stage i nonseminomatous germ cell tumor. J Urol; 163 (6): 1785–1787PubMedCrossRefGoogle Scholar
  49. Sturgeon JF, Jewett MA, Alison RE et al. (1992) Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors. J Clin Oncol 10 (4): 564–568PubMedGoogle Scholar
  50. Swanson D, Johnson DE (1989) M. D. Anderson experience with surveillance for clinical stage I disease. In: Johnson DE, Logothetis CJ, von Eschenbach AC (eds) Systemic therapy for genitourinary cancers. Year Book Medical Publishers, Chicago, pp 304–311Google Scholar
  51. Tandstad T, Olav D, Cohn-Cedermark G, Cavallin-Stahl E, Stierner UK, Solberg A, Bremnes RM, Langberg CW, Klepp OH (2008) Risk-adapted treatment in clinical stage I (CSI) nonseminomatous germ cell testicular cancer (NSGCT) J Clin Oncol 26 abstr 5034Google Scholar
  52. Travis LB, Curtis RE, Storm H et al. (1997) Risk of second malignant neoplasms among long-term survivors of testicular cancer [see comments]. J Natl Cancer Inst 89 (19): 1429–1439PubMedCrossRefGoogle Scholar
  53. Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, Andersson M, Kaijser M, Gospodarowicz M, Joensuu T, Cohen RJ, Boice JD Jr, Dores GM, Gilbert ES (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97:1354–1365PubMedCrossRefGoogle Scholar
  54. Van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MWJ, Ribot JG, Hoekstra HJ, Ouwens GM, Aleman BMP, van Leeuwen FE (2007) Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25 (28):4370–4378PubMedCrossRefGoogle Scholar
  55. Vergouwe Y, Steyerberg EW, Eijkemans MJ, Albers P, Habbema JD (2003) Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol 21:4092–9PubMedCrossRefGoogle Scholar
  56. Westermann DH, Schefer H, Thalmann GN, Karamitopoulou-Diamantis E, Fey MF, Studer UE (2008) Long-term follow-up results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I non-seminomatous germ cell tumors of the testis. J Urol 179: 163–6PubMedCrossRefGoogle Scholar
  57. Zagars GK, Ballo MT, Lee AK, Strom SS (2004) Mortality after cure of testicular seminoma. J Clin Oncol 22:640–647PubMedCrossRefGoogle Scholar

Literatur zu Kap. 26.8

  1. Albers P, Bender H, Yilmaz H et al. (1999) Positron emission tomography in the clinical staging of patients with stage I and II germ cell tumors. Urology 53: 808–811PubMedCrossRefGoogle Scholar
  2. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Horwich A, Klepp O, Laguna MP, Pizzocaro G (2005) Guidelines on Testicular Cancer. Eur Urol 48: 885–894PubMedCrossRefGoogle Scholar
  3. Arranz Arija JA, Garía del Muro X, Gumà J et al. (2001) E400P in advanced seminoma of good prognosis according to the International Germ Cell Cancer Collaborative Group (IGCCCG) classification: The Spanish Germ Cell Cancer Group experience. Ann Oncol 12: 487–491PubMedCrossRefGoogle Scholar
  4. Ball D, Barrett A, Peckham MJ (1982) The management of metastatic seminoma testis. Cancer 50: 2289–2294PubMedCrossRefGoogle Scholar
  5. Bamberg M, Schmidberger H, Meisner C et al. (1999) Radiotherapy for stage I, IIA/B testicular seminoma. Int J Cancer 83: 823–827PubMedCrossRefGoogle Scholar
  6. Borski A (1973) Diagnosis, staging and natural history of testicular seminoma. Cancer 32: 1202–1206PubMedCrossRefGoogle Scholar
  7. Busch FM, Sayegh ES, Shenault OW Jr. (1965) Some uses of lymphangiography in the management of testicular tumors. J Urol 93: 490–495PubMedGoogle Scholar
  8. Chung PW, Gospodarowicz MK, Panzarella T et al. (2004) Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol 45: 754–759PubMedCrossRefGoogle Scholar
  9. Classen J, Schmidberger H, Meisner C et al. (2003) Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 21: 1101–1106PubMedCrossRefGoogle Scholar
  10. Classen J, Schmidberger H, Meisner C et al. (2004) Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG). Br J Cancer 90: 2305–2311PubMedGoogle Scholar
  11. Deutsche Krebsgesellschaft e. V. (2002) Qualitätssicherung in der Onkologie — Leitlinie zur Diagnostik und Therapie von Hodentumoren auf der Grundlage evidenzbasierter Medizin (EBM). In: Souchon R, Schmoll H-J, Krege S (Hrsg) Zuckschwerdt, MünchenGoogle Scholar
  12. Ferlay J, Bray F, Pisani P et al. (2001) GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancer Base No. 5, Lyon: IARC 2001 (auch: www.iarc.fr/globocan/database.pdf)Google Scholar
  13. Garcia-del-Muro X, Maroto P, Gumà J et al. (2008) Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: A Spanish Germ Cell Cancer Group Study. J Clin Oncol 26: 5416–5421PubMedCrossRefGoogle Scholar
  14. Gilbert DC, Vanas NJ, Beesley S, Bloomfield D et al. (2009) Treating IIA/B seminoma with combination carboplatin and radiotherapy. J Clin Oncol Mar 16, 2009 [Epub ahead of print]Google Scholar
  15. Gospodarowicz MK, Sturgeon JFG, Jewett MAS (1998) Early stage and advanced seminoma: role of radiation therapy, surgery, and chemotherapy. Semin Oncol 25: 160–173Google Scholar
  16. Huddart R, Kataja V (2008) ESMO Guidelines Working Group. Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 Suppl 2:ii49–51PubMedCrossRefGoogle Scholar
  17. Huyghe E, Matsuda T, Thonneau P (2003) Increasing incidence of testicular cancer worldwide: a review. J Urol 170: 5–11PubMedCrossRefGoogle Scholar
  18. Jones WG, Fossa SD, Mead GM et al. (2005) Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 23: 1200–1208PubMedCrossRefGoogle Scholar
  19. Krege S, Souchon R, Schmoll HJ (2001) Interdisciplinary Consensus on diagnosis and treatment of testicular germ cell tumors: result of an update conference on evidence-based medicine (EBM). Eur Urol 40: 372–391PubMedCrossRefGoogle Scholar
  20. Krege S, Boergemann C, Baschek R et al. (2006) Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). Ann Oncol 17: 276–280PubMedCrossRefGoogle Scholar
  21. Krege S, Beyer J, Souchon R et al. (2008) European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. Eur Urol 53: 497–513PubMedCrossRefGoogle Scholar
  22. Krug B, Heidenreich A, Dietlein M et al. (1999) Lymphknotenstaging maligner testikulärer Keimzelltumoren. Fortschr Röntgenstr 171: 87–94CrossRefGoogle Scholar
  23. Lashley D, Lowe B (1998) A rational approach to managing stage I non-seminomatous germ cell cancer. Urol Clin North Am 25: 405–423PubMedCrossRefGoogle Scholar
  24. Lassen U, Daugaard G, Eigtved A et al. (2003) Wholebody positron emission tomography (PET) with FDG in patients with stage I non-seminomatous germ cell tumours (NSGCT). Eur J Nucl Med Imaging 30: 396–402Google Scholar
  25. Leibovitch I, Foster RS, Kopecky KK et al. (1995) Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell tumor using size criteria of retroperitoneal lymph nodes. J Urol 154: 1759–1763PubMedCrossRefGoogle Scholar
  26. Leibovitch I, Foster RS, Kopecky KK et al. (1998) Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: A combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment. J Clin Oncol 16: 261–268PubMedGoogle Scholar
  27. Milosevic MF, Gospodarowicz M, Warde P (1999) Management of testicular seminoma. Semin Surg Oncol 17: 240–249PubMedCrossRefGoogle Scholar
  28. Oxford Centre for Evidence based Medicine (2001) Levels of Evidence. http://minerva.minervation.com/cebm/Google Scholar
  29. Patterson H, Norman AR, Mitra SS et al. (2001) Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother Oncol 59: 5–11PubMedCrossRefGoogle Scholar
  30. Purdue MP, Devesa SS, Sigurdson AJ, McGlynn KA (2005) International patterns and trends in testis cancer incidence. Int J Cancer 115: 822–827PubMedCrossRefGoogle Scholar
  31. Ray B, Hajdu SI, Whitmore WF (1974) Distribution of retroperitoneal lymph node metastases in germinal tumors. Cancer 33: 340–348PubMedCrossRefGoogle Scholar
  32. Schmidberger H, Bamberg M (1995) Therapieoptionen bei testikulären Seminomen in den frühen Stadien. Strahlenther Onkol 171: 125–139PubMedGoogle Scholar
  33. Schmidberger H, Bamberg M, Meisner C et al. (1997) Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study. Int J Radiol Oncol Biol Phys 39: 321–326CrossRefGoogle Scholar
  34. Schmoll HJ, Souchon R, Krege S et al. (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15: 1377–1399PubMedCrossRefGoogle Scholar
  35. Smalley SR, Evans RG (1996) Seminoma: management of stage II disease, posttherapy residual masses, and other special considerations. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds.) Comprehensive Textbook of Genitourinary Oncology. Williams u. Wilkins, Baltimore, pp 1038–1049Google Scholar
  36. Sobin LH, Wittekind Ch (eds.) (2002) UICC: TNM classification of malignant tumours, 6th edn, Wiley-Liss, New YorkGoogle Scholar
  37. Souchon R, Krege S, Schmoll HJ et al. für die German Testicular Cancer Study Group (GTCSG) (2000) Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren: Ergebnisse einer Update-Konferenz auf Grundlage evidenzbasierter Medizin (EBM). Strahlenther Onkol 176: 388–405PubMedCrossRefGoogle Scholar
  38. Spermon JR, De Geus-Oei LF, Kiemeney LA et al. (2002) The role of (18) fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. Brit J Urol Int 89: 549–556Google Scholar
  39. Thomas GM, Williams SD (1998) Testis. In: Perez CA, Brady LW (eds) Principles and Practice of Radiation Oncology. Lippincott-Raven Publisher, Philadelphia, pp 1695–1715Google Scholar
  40. Vallis KA, Howard GC, Duncan W, Cornbleet MA, Kerr GR (1995) Radiotherapy for stages I and II testicular seminoma: results and morbidity in 238 patients. Br J Radiol 68: 400–405PubMedCrossRefGoogle Scholar
  41. von der Maase H (2001) Do we have a new standard of treatment for patients with seminoma stage IIA and stage IIB? Radiother Oncol 59: 1–3PubMedCrossRefGoogle Scholar
  42. Warde P, Gospodarowicz M, Panzarella T et al. (1998) Management of stage II seminoma. J Clin Oncol 16: 290–294PubMedGoogle Scholar
  43. Weissbach L, Boedefeld EA (1987) Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. J Urol 138: 77–82PubMedGoogle Scholar
  44. Weissbach L, Bussar-Maatz R, Löhrs U et al. (1999) Prognostic factors in seminomas with special respect to HCG: results of a prospective multicenter study. Seminoma Study Group. Eur Urol 36: 601–608PubMedCrossRefGoogle Scholar
  45. Whipple GL, Sagerman RH, van Rooy EM (1997) Long-term evaluation of postorchiectomy radiotherapy for stage II seminoma. Am J Clin Oncol 20: 196–201PubMedCrossRefGoogle Scholar
  46. White PM, Howard GC, Best JJ, Wright AR (1997) The role of computed tomographic examination of the pelvis in the management of testicular germ cell tumours. Clin Radiol 52: 124–129PubMedCrossRefGoogle Scholar
  47. Yao WQ, Fossa SD, Dearnaley D, Horwich A (1994) Combined single course carboplatin with radiotherapy in treatment of Stage IIA,B seminoma — a preliminary report. Radiother Oncol 33: 88–90PubMedCrossRefGoogle Scholar
  48. Zagars GK, Pollack A (2001) Radiotherapy for stage II testicular seminoma. Int J Radiat Oncol Biol Phys 51: 643–649PubMedGoogle Scholar

Literatur zu Kap. 26.9

  1. Albers P, Albers J, Cummings OW, Boris M, Donohue JP, Foster RS (1995) Flow cytometric and cytophotometric DNA analysis cannot predict subsequent tumour recurrence in pathological stage IIA/B non-seminomatous testicular germ cell tumour patients who do not receive adjuvant chemotherapy [letter]. Eur J Cancer 31A (5):848–849PubMedCrossRefGoogle Scholar
  2. Beck SD, Cheng L, Bihrle R, Donohue JP, Foster RS (2007) Does the presence of extranodal extension in pathological stage B1 non-seminomatous germ cell tumor necessitate adjuvante chemotherapy? J Urol 177: 944–6PubMedCrossRefGoogle Scholar
  3. De Wit M, Hartmann M, Kotzerke J, Wirth M, Brenner W, Hellwig D, Lehmann J, Heicappell R, Bokemeyer C, Bares R (2005) German Multicenter PET Study Group 18F-FDG-PET in clinical stage I and II non-seminomatous germ cell tumors: first results of the German multicenter trial. J Clin Oncol 23: 4504 (Supplement)Google Scholar
  4. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R (1995) Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965–1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer 31A (10): 1599–1604PubMedCrossRefGoogle Scholar
  5. Hartlapp JH, Weissbach L, Bussar-Maatz R (1987) Adjuvant chemotherapy in nonseminomatous testicular tumour stage II. Int J Androl 10 (1): 277–284PubMedCrossRefGoogle Scholar
  6. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin. 55: 10–30PubMedCrossRefGoogle Scholar
  7. Kondagunta GV, Sheinfeld J, Mazumdar M, Mariani TV, Bajorin D, Bacik J, Bosl GJ, Motzer RJ (2004) Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. Journal of Clinical Oncology 22: 464–467PubMedCrossRefGoogle Scholar
  8. Richie JP, Kantoff PW (1991): Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer? J Clin Oncol 9 (8): 1393–1396PubMedGoogle Scholar
  9. Schmoll HJ, Souchon R, Krege S et al. and the European Germ Cell Cancer Consensus Group (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15: 1377–1399PubMedCrossRefGoogle Scholar
  10. Sesterhenn IA, Weiss RB, Mostofi FK et al. (1992) Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study. J Clin Oncol 10 (1): 69–78PubMedGoogle Scholar
  11. Sheinfeld J, Motzer RJ, Rabbani F, McKiernan J, Bajorin D, Bosl GJ (2003) Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and II A nonseminomatous germ cel tumors. Journal of Urology 170: 1159–62PubMedCrossRefGoogle Scholar
  12. Sonneveld DJ, Hoekstra HJ, Van Der Graaf WT, Sluiter WJ, Schraffordt Koops H, Sleijfer DT (1999) The changing distribution of stage in nonseminomatous testicular germ cell tumours, from 1977 to 1996. BJU Int. 84:68–74PubMedCrossRefGoogle Scholar
  13. Steiner H, Peschel R, Janetschek G, Holtl L, Berger AP, Bartsch G, Hobisch A (2004) Long-term results of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience. Urology. 63:550–555PubMedCrossRefGoogle Scholar
  14. Steiner H, Muller T, Gozzi C, Akkad T, Bartsch G, Berger AP (2006) Related Articles, Links. Two cycles of cisplatin-based chemotherapy for low-volume retroperitoneal stage II nonseminomatous germ cell tumours. BJU Int 98 (2): 349–352 (Epub 2006 Apr 18)PubMedCrossRefGoogle Scholar
  15. Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF, Sheinfeld J (2005) Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: Impact of patient selection factors on outcome. J Clin Oncol 23:2781–2788PubMedCrossRefGoogle Scholar
  16. Weissbach L, Hartlapp JH (1991) Adjuvant chemotherapy of metastatic stage II nonseminomatous testis tumor. J Urol 146 (5): 1295–1298PubMedGoogle Scholar
  17. Weissbach L, Bussar-Maatz R, Flechtner H, Pichlmeier U, Hartmann M, Keller L (2000) RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol 37 (5): 582–594PubMedCrossRefGoogle Scholar
  18. Williams SD, Stablein DM, Einhorn LH et al. (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317 (23): 1433–1438PubMedCrossRefGoogle Scholar

Literatur zu Kap. 26.10

  1. International Germ Cell Consensus Classification (1997) a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15: 594–603Google Scholar
  2. Albers P (2004) Resection of retroperitoneal residual tumor after chemotherapy for testicular cancer indication and surgical techniques. Crit Rev Oncol Hematol 50: 79–85PubMedCrossRefGoogle Scholar
  3. Albers P, Weissbach L, Krege S, Kliesch S, Hartmann M, Heidenreich A, Walz P, Kuczyk M, Fimmers R (2004) Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol 171: 1835–1838PubMedCrossRefGoogle Scholar
  4. Aprikian AG, Herr HW, Bajorin DF, Bosl GJ (1994) Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer 74: 1329–1334PubMedCrossRefGoogle Scholar
  5. Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, Geller NL, Fair WR, Herr H, Sogani P (1993) Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 11: 598–606PubMedGoogle Scholar
  6. Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP (1995) Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 153: 976–980PubMedCrossRefGoogle Scholar
  7. Besse B, Flechon A, Caty A, Chevreau C, Culine S, Grunenwald D, Fizazi K (2005) No need for contralateral lung surgery in case of evidence of post-chemotherapy necrosis alone in residual lung masses in patients with disseminated non seminomatous germ cell tumors. Proc Am Soc Clin Oncol 24 (abstr. 4524)Google Scholar
  8. Birch R, Williams S, Cone A, Einhorn L, Roark P, Turner S, Greco FA (1986) Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4: 400–407PubMedGoogle Scholar
  9. Bokemeyer C, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Schmoll HJ, Kanz L, Einhorn L, Nichols CR, Hartmann JT (2001) Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome. Cancer 91: 1394–1401PubMedCrossRefGoogle Scholar
  10. Bokemeyer C, Kohrmann O, Tischler J, Weissbach L, Rath U, Haupt A, Schoffski P, Harstrick A, Schmoll HJ (1996) A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ‘good-risk’ metastatic non-seminomatous germ cell tumors. Ann Oncol 7: 1015–1021PubMedGoogle Scholar
  11. Bokemeyer C, Kollmannsberger C, Flechon S, Stenning S, Droz JP, Horwich A, Clemm C, Fossa SD, Hartmann JT, Rueckerl C-P, Kanz L (2002) Prognostic factors in patients (pts) with advanced metastatic seminoma (SEM) treated with either single agent carboplatin (CP) or cisplatin-based (DDP) combination chemotherapy (CTX): a meta-analysis of prospective European trials. Proc Am Soc Clin Oncol 21: 186a (abstr. 740)Google Scholar
  12. Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C (1999) First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol 17: 3450–3456PubMedGoogle Scholar
  13. Bokemeyer C, Oechsle K, Hartmann JT, Schoffski P, Schleucher N, Metzner B, Schleicher J, Kanz L (2002) Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. Br J Cancer 87: 1066–1071PubMedCrossRefGoogle Scholar
  14. Bokemeyer C, Schleucher N, Metzner B, Thomas M, Rick O, Schmoll HJ, Kollmannsberger C, Boehlke I, Kanz L, Hartmann JT (2003) Firstline sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial. Br J Cancer 89: 29–35PubMedCrossRefGoogle Scholar
  15. Bosl GJ, Geller NL, Bajorin D, Leitner SP, Yagoda A, Golbey RB, Scher H, Vogelzang NJ, Auman J, Carey R (1988) A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 6: 1231–1238PubMedGoogle Scholar
  16. Bosl GJ, Geller NL, Cirrincione C, Vogelzang NJ, Kennedy BJ, Whitmore WE, Jr., Vugrin D, Scher H, Nisselbaum J, Golbey RB (1983) Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43: 3403–3407PubMedGoogle Scholar
  17. Brenner PC, Herr HW, Morse MJ, Sheinfeld J, Aprikian A, Bosl GJ, Motzer RJ, Bajorin DF, Schantz S, Fair WR, Burt M (1996) Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. J Clin Oncol 14: 1765–1769PubMedGoogle Scholar
  18. Christian JA, Huddart RA, Norman A, Mason M, Fossa S, Aass N, Nicholl EJ, Dearnaley DP, Horwich A (2003) Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol 21: 871–877PubMedCrossRefGoogle Scholar
  19. Clemm C, Bokemeyer C, Gerl A, Holzel D, Weissbach L, Bamberg M, Schoffski P, Harstrick A, Schmoll HJ, Wilmanns W (2000) Randomized Trial Comparing Cisplatin/Etoposide/Ifosfamide with Carboplatin Monochemotherapy in Patients with Advanced Metastatic Seminoma. Proc Am Soc Clin Oncol 19: 326a (abstr. 1283)Google Scholar
  20. Clemm C, Gerl A, Hentrich M (1995) Chemotherapy for far advanced seminoma. Onkologie 18: 189 (abstr. 909)CrossRefGoogle Scholar
  21. Collette L, Sylvester RJ, Stenning SP, Fossa SD, Mead GM, De Wit R, de Mulder PH, Neymark N, Lallemand E, Kaye SB (1999) Impact of the treating institution on survival of patients with “poor-prognosis” metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 91: 839–846PubMedCrossRefGoogle Scholar
  22. Collins Dh, Pugh RC (1964) classification and frequency of testicular tumours. Br J Urol 36: Suppl 11Google Scholar
  23. Coogan CL, Hejase MJ, Wahle GR, Foster RS, Rowland RG, Bihrle R, Donohue JP (1996) Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol 156: 1656–1658PubMedCrossRefGoogle Scholar
  24. Culine S, Kerbrat P, Kramar A, Theodore C, Chevreau C, Geoffrois L, Bui NB, Peny J, Caty A, Delva R, Biron P, Fizazi K, Bouzy J, Droz JP (2007) Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUS T93BP). Ann Oncol 18: 917–924PubMedCrossRefGoogle Scholar
  25. Culine S, Kramar A, Theodore C, Geoffrois L, Chevreau C, Biron P, Nguyen BB, Heron JF, Kerbrat P, Caty A, Delva R, Fargeot P, Fizazi K, Bouzy J, Droz JP (2008) Randomized trial comparing bleomycin/ etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate-and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol 26: 421–427PubMedCrossRefGoogle Scholar
  26. De Santis M, Bokemeyer C, Becherer A, Stoiber F, Oechsle K, Kletter K, Dohmen BM, Dittrich C, Pont J (2001) Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 19: 3740–3744PubMedGoogle Scholar
  27. De Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fossa SD, Cook P, de Prijck L, Stenning S, Collette L (2001) Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3-or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19: 1629–1640PubMedGoogle Scholar
  28. De Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, Bokkel Huinink WW, Rea LA, Collette L, Sylvester R (1997) Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15: 1837–1843PubMedGoogle Scholar
  29. De Wit R, Stoter G, Sleijfer DT, Kaye SB, de Mulder PH, Bokkel Huinink WW, Spaander PJ, de Pauw M, Sylvester R (1995) Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Gentitourinary Tract Cancer Cooperative Group. Br J Cancer 71: 1311–1314PubMedGoogle Scholar
  30. De Wit R, Stoter G, Sleijfer DT, Neijt JP, Bokkel Huinink WW, de Prijck L, Collette L, Sylvester R (1998) Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 78: 828–832PubMedGoogle Scholar
  31. Donadio AC, Motzer RJ, Bajorin DF, Kantoff PW, Sheinfeld J, Houldsworth J, Chaganti RS, Bosl GJ (2003) Chemotherapy for teratoma with malignant transformation. J Clin Oncol 21: 4285–4291PubMedCrossRefGoogle Scholar
  32. Donohue JP, Fox EP, Williams SD, Loehrer PJ, Ulbright TM, Einhorn LH, Weathers TD (1994) Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection: outcome analysis. World J Urol 12: 190–195PubMedGoogle Scholar
  33. Droz JP, Culine S, Bouzy J, Theodore C, Geoffrois L, Biron P, Bui BN, Peny J, Kerbrat P, Chevreau C, Delva R, Fargeot P, Platini C, Fizazi K, Caty A, Kramar A (2001) Preliminary Results of a Randomized Trial Comparing Bleomycin, Etoposide, Cisplatin (BEP) and Cyclophosphamide, Doxorubicin, Cisplatin/Vinblastin, Bleomycin (CISCA/VB) for Patients (Pts) with Intermediate-and Poor-Risk Metastatic Non Seminomatous Germ-Cell Tumors (NSGCT). Proc Am Soc Clin Oncol 20: 173a (abstr. 690)Google Scholar
  34. Duchesne GM, Stenning SP, Aass N, Mead GM, Fossa SD, Oliver RT, Horwich A, Read G, Roberts IT, Rustin G, Cullen MH, Kaye SB, Harland SJ, Cook PA (1997) Radiotherapy after chemotherapy for metastatic seminoma — a diminishing role. MRC Testicular Tumour Working Party.Eur J Cancer 33: 829–835PubMedCrossRefGoogle Scholar
  35. Einhorn LH, Williams SD, Mandelbaum I, Donohue JP (1981) Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer 48: 904–908PubMedCrossRefGoogle Scholar
  36. Ellison MF, Mostofi FK, Flanigan RC (1988) Treatment of the residual retroperitoneal mass after chemotherapy for advanced seminoma. J Urol 140: 618–620PubMedGoogle Scholar
  37. Feuer EJ, Sheinfeld J, Bosl GJ (1999) Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer. J Natl Cancer Inst 91: 816–818PubMedCrossRefGoogle Scholar
  38. Fizazi K, Culine S, Chen I (2004) Oxaliplatin in non-seminomatous germ-cell tumors. Ann Oncol 15: 1295PubMedCrossRefGoogle Scholar
  39. Fizazi K, Dunant A, Oldenburg J, Chen I, Salvioni R, Hartmann J, Daugaard G, Flechon A, Bouzy J, Fromont G, on behalf of an International Study Group (2005) Viable malignant cells after primary chemotherapy for disseminated non-seminomatous germ-cell tumors (NSGCT): An international validation study. Proc Am Soc Clin Oncol 24 (abstr. 4521)Google Scholar
  40. Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ (2002) Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer 86: 1555–1560PubMedCrossRefGoogle Scholar
  41. Fizazi K, Tjulandin S, Salvioni R, Germa-Lluch JR, Bouzy J, Ragan D, Bokemeyer C, Gerl A, Flechon A, de Bono JS, Stenning S, Horwich A, Pont J, Albers P, De Giorgi U, Bower M, Bulanov A, Pizzocaro G, Aparicio J, Nichols CR, Theodore C, Hartmann JT, Schmoll HJ, Kaye SB, Culine S, Droz JP, Mahe C (2001) Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy-results from an international study group. J Clin Oncol 19: 2647–2657PubMedGoogle Scholar
  42. Fossa SD, Borge L, Aass N, Johannessen NB, Stenwig AE, Kaalhus O (1987) The treatment of advanced metastatic seminoma: experience in 55 cases. J Clin Oncol 5: 1071–1077PubMedGoogle Scholar
  43. Fossa SD, Droz JP, Stoter G, Kaye SB, Vermeylen K, Sylvester R (1995) Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group. Br J Cancer 71: 619–624PubMedGoogle Scholar
  44. Fossa SD, Ous S, Lien HH, Stenwig AE (1989) Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol 141: 557–559PubMedGoogle Scholar
  45. Fox EP, Weathers TD, Williams SD, Loehrer PJ, Ulbright TM, Donohue JP, Einhorn LH (1993) Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 11: 1294–1299PubMedGoogle Scholar
  46. Friedman NB (1987) The function of the primordial germ cell in extragonadal tissues. Int J Androl 10: 43–49PubMedCrossRefGoogle Scholar
  47. Ganjoo KN, Chan RJ, Sharma M, Einhorn LH (1999) Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol 17: 3457–3460PubMedGoogle Scholar
  48. Gels ME, Nijboer AP, Hoekstra HJ, Sleijfer DT, Molenaar WM, Plukker JT, Droste JH, Schraffordt KH (1997) Complications of the postchemotherapy resection of retroperitoneal residual tumour mass in patients with non-seminomatous testicular germ cell tumours. Br J Urol 79: 263–268PubMedGoogle Scholar
  49. Gerl A, Clemm C, Schmeller N, Dienemann H, Lamerz R, Kriegmair M, Wilmanns W (1995) Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours. Ann Oncol 6: 483–488PubMedGoogle Scholar
  50. Gerl A, Clemm C, Schmeller N, Dienemann H, Weiss M, Kriegmair M, Lohrs U, Wilmanns W (1994) Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours. Br J Cancer 70: 960–965PubMedGoogle Scholar
  51. Gholam D, Fizazi K, Terrier-Lacombe MJ, Jan P, Culine S, Theodone C (2003) Advanced seminoma-treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients. Cancer 98: 745–752PubMedCrossRefGoogle Scholar
  52. Gregory C, Peckham MJ (1986) Results of radiotherapy for stage II testicular seminoma. Radiother Oncol 6: 285–292PubMedCrossRefGoogle Scholar
  53. Hahn TL, Jacobson L, Einhorn LH, Foster R, Goulet RJ, Jr. (1999) Hepatic resection of metastatic testicular carcinoma: a further update. Ann Surg Oncol 6: 640–644PubMedCrossRefGoogle Scholar
  54. Hartmann JT, Bamberg M, Albers M, Clemm C, Souchon R, Oechsle K, Weissbach L, Kanz L, Bokemeyer C (2003) Multidisciplinary treatment and prognosis of patients (pts) with central nervous system metastases (CNS) from testicular germ cell tumor (GCT) origin. Proc Am Soc Clin Oncol 22: 400 (abstr. 1607)Google Scholar
  55. Hartmann JT, Candelaria M, Kuczyk MA, Schmoll HJ, Bokemeyer C (1997) Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer 33: 843–847PubMedCrossRefGoogle Scholar
  56. Hartmann JT, Classen J, Bokemeyer C (2003) Chemotherapie bei Keimzelltumoren mit intermediärer und schlechter Prognose. Onkologie 9: 985–991CrossRefGoogle Scholar
  57. Hartmann JT, Einhorn L, Nichols CR, Droz JP, Horwich A, Gerl a, Fossa SD, Beyer J, Pont J, Schmoll HJ, Kanz L, Bokemeyer C (2001) Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. J Clin Oncol 19: 1641–1648PubMedGoogle Scholar
  58. Hartmann JT, Nichols CR, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Einhorn L, Kanz L, Bokemeyer C (2000) The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors. Cancer 88: 2629–2635PubMedCrossRefGoogle Scholar
  59. Hartmann JT, Nichols CR, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Fizazi K, Einhorn L, Kanz L, Bokemyer C (2000) Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. J Natl Cancer Inst 92: 54–61PubMedCrossRefGoogle Scholar
  60. Hartmann JT, Nichols CR, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Kanz L, Einhorn L, Bokemeyer C (2002) Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol 13: 1017–1028PubMedCrossRefGoogle Scholar
  61. Hartmann JT, Rick O, Oechsle K, Kuczyk M, Gauler T, Schoffski P, Schleicher J, Mayer F, Teichmann R, Kanz L, Bokemeyer C (2005) Role of postchemotherapy surgery in the management of patients with liver metastases from germ cell tumors. Ann Surg 242: 260–266PubMedCrossRefGoogle Scholar
  62. Hartmann JT, Schleucher N, Metzner B, Kohne CH, Gerl A, Schleicher J, Rick O, Derigs HG, Beyer J, Boehlke I, Kanz I, Bokemeyer C (2001) Phase I/II study of sequential high dose VIP plus paclitaxel supported by PBSC in patients with, poor prognosis’ germ cell tumor (GCT). Proc Am Soc Clin Oncol 20: 173a (abstr. 691)Google Scholar
  63. Hartmann JT, Schmoll HJ, Kuczyk MA, Candelaria M, Bokemeyer C (1997) Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Ann Oncol 8: 531–538PubMedCrossRefGoogle Scholar
  64. Hartmann JT, Gauler T, Metzner B, Gerl A, Casper J, Rick O, Horger M, Schleicher J, Derigs G, Mayer-Steinacker R, Beyer J, Kuczyk MA, Bokemeyer C (2007) Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group. J Clin Oncol 25: 5742–5747PubMedCrossRefGoogle Scholar
  65. Hendry WF, A’Hern RP, Hetherington JW, Peckham MJ, Dearnaley DP, Horwich A (1993) Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumour: prognostic value and therapeutic benefit. Br J Urol 71: 208–213PubMedCrossRefGoogle Scholar
  66. Herr HW, Sheinfeld J, Puc HS, Heelan R, Bajorin DF, Mencel P, Bosl GJ, Motzer RJ (1997) Surgery for a post-chemotherapy residual mass in seminoma. J Urol 157: 860–862PubMedCrossRefGoogle Scholar
  67. Hinton S, Catalano PJ, Einhorn LH, Nichols CR, David CE, Vogelzang N, Trump D, Loehrer PJ Sr. (2003) Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer 97: 1869–1875PubMedCrossRefGoogle Scholar
  68. Horwich A, Dearnaley DP, A’Hern R, Mason M, Thomas G, Jay G, Nicholls J (1992) The activity of single-agent carboplatin in advanced seminoma. Eur J Cancer 28A: 1307–1310PubMedCrossRefGoogle Scholar
  69. Horwich A, Oliver RT, Wilkinson PM, Mead GM, Harland SJ, Cullen MH, Roberts JT, Fossa SD, Dearnaley DP, Lallemand E, Stenning SP (2000) A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party. Br J Cancer 83: 1623–1629PubMedCrossRefGoogle Scholar
  70. Horwich A, Paluchowska B, Norman A, Huddart R, Nicholls J, Fisher C, Husband J, Dearnaley DP (1997) Residual mass following chemotherapy of seminoma. Ann Oncol 8: 37–40PubMedCrossRefGoogle Scholar
  71. Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, De Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP (1997) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15: 1844–1852PubMedGoogle Scholar
  72. Jones DM, Amato RJ, Pagliaro LC, Millikan R, Ellherhorst J, Tu SM, Logothetis CJ (1997) Carboplatin (CBDCA) and cyclophosphamide (CTX) and delayed selective consolidation in advanced seminoma (Meeting abstract). Proc Am Soc Clin Oncol 16: 323a (abstr. 1149)Google Scholar
  73. Kaye SB, Mead GM, Fossa S, Cullen M, deWit R, Bodrogi I, Van Groeningen C, Sylvester R, Collette L Stenning S, de Prijck L, Lallemand E, deMulder P (1998) Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 16: 692–701PubMedGoogle Scholar
  74. Kopp HG, Kuczyk M, Classen J, Stenzl A, Kanz L, Mayer F, Bamberg M, Hartmann JT (2006) Advances in the treatment of testicular cancer. Drugs 66(5): 641–659PubMedCrossRefGoogle Scholar
  75. Loehrer PJ, Sr., Birch R, Williams SD, Greco FA, Einhorn LH (1987) Chemotherpy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol 5: 1212–1220PubMedGoogle Scholar
  76. Loehrer PJ Sr., Johnson D, Elson P, Einhorn LH, Trump D (1995) Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 13: 470–476PubMedGoogle Scholar
  77. Loehrer PJ, Lauer R, Roth BJ, Williams SD, Kalasinski LA, Einhorn LH (1998) Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 109: 540–546Google Scholar
  78. Logothetis CJ, Samuels ML, Ogden SL, Dexeus FH, Chong CD (1987) Cyclophosphamide and sequential cisplatin for advanced seminoma: long-term followup in 52 patients. J Urol 138: 789–794PubMedGoogle Scholar
  79. Mead GM, Stenning SP (1997) The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. Clin Oncol (R Coll Radiol) 9: 207–209Google Scholar
  80. Mencel PJ, Motzer RJ, Mazumdar M, Vlamis V, Bajorin DF, Bosl GJ (1994) Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 12: 120–126PubMedGoogle Scholar
  81. Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, Bajorin DF, Lara PN, Jr., Einhorn L, Mazumdar M, Bosl GJ (2007) Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25: 247–256PubMedCrossRefGoogle Scholar
  82. Mulders PF, Oosterhof GO, Boetes C, de Mulder PH, Theeuwes AG, Debruyne FM (1990) The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumours. Br J Urol 66: 425–429PubMedCrossRefGoogle Scholar
  83. Murphy BA, Motzer RJ, Mazumdar M, Vlamis V, Nisselbaum J, Bajorin D, Bosl GJ (1994) Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer 73: 2520–2526PubMedCrossRefGoogle Scholar
  84. Napier MP, Naraghi A, Christmas TJ, Rustin GJ (2000) Long-term follow-up of residual masses after chemotherapy in patients with non-seminomatous germ cell tumours. Br J Cancer 83: 1274–1280PubMedCrossRefGoogle Scholar
  85. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ (1998) Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 16: 1287–1293PubMedGoogle Scholar
  86. Nichols CR, Roth BJ, Heerema N, Griep J, Tricot G (1990) Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med 322: 1425–1429PubMedCrossRefGoogle Scholar
  87. Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J, Miller ME, Bartolucci A, Schacter L, Einhorn LH (1991) Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Study Group and Southwest Oncology Group protocol. J Clin Oncol 9: 1163–1172PubMedGoogle Scholar
  88. Oechsle K, Hartmann M, Brenner W, Venz S, Weissbach L, Franzius C, Kliesch S, Mueller S, Krege S, Heicappell R, Bares R, Bokemeyer C, de Wit M (2008) [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol 26: 5930–5935PubMedCrossRefGoogle Scholar
  89. O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A (2003) Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 14: 91–96PubMedCrossRefGoogle Scholar
  90. Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD (2003) Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 21: 3310–3317PubMedCrossRefGoogle Scholar
  91. Ozols RF, Ihde DC, Linehan WM, Jacob J, Ostchega Y, Young RC (1988) A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 6: 1031–1040PubMedGoogle Scholar
  92. Pizzocaro G, Salvioni R, Piva L, Zanoni F, Milani A, Faustini M (1986) Cisplatin combination chemotherapy in advanced seminoma. Cancer 58: 1625–1629PubMedCrossRefGoogle Scholar
  93. Puc HS, Heelan R, Mazumdar M, Herr H, Scheinfeld J, Vlamis V, Bajorin DF, Bosl GJ, Mencel P, Motzer RJ (1996) Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 14: 454–460PubMedGoogle Scholar
  94. Rivoire M, Elias D, De Cian F, Kaemmerlen P, Theodore C, Droz JP (2001) Multimodality treatment of patients with liver metastases from germ cell tumors: the role of surgery. Cancer 92: 578–587PubMedCrossRefGoogle Scholar
  95. Saxman SB, Finch D, Gonin R, Einhorn LH (1998) Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol 16: 702–706PubMedGoogle Scholar
  96. Schmoll HJ, Harstrick A, Bokemeyer C, Dieckmann KP, Clemm C, Berdel WE, Souchon R, Schober C, Wille H, Poliwoda H (1993) Singleagent carboplatinum for advanced seminoma. A phase II study. Cancer 72: 237–243PubMedCrossRefGoogle Scholar
  97. Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schoffski P, Schleicher J, Rick O, Beyer J, Hossfeld DK, Kanz L, Berdel WE, Andreesen R, Bokemeyer C (2003) Long-term results of first-line sequential high dose VIP chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: An extended phase II study of the german testicular cancer study group. J Clin Oncol 23: 4083–4091CrossRefGoogle Scholar
  98. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE, De Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, de Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, Paz AL, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, De Wit M, Derigs HG, Dieckmann KP, Flasshove M, Garcia dM, X, Gerl A, Germa-Lluch JR, Hartmann M, Heidenreich A, Hoeltl W, Joffe J, Jones W, Kaiser G, Klepp O, Kliesch S, Kisbenedek L, Koehrmann KU, Kuczyk M, Laguna MP, Leiva O, Loy V, Mason MD, Mead GM, Mueller RP, Nicolai N, Oosterhof GO, Pottek T, Rick O, Schmidberger H, Sedlmayer F, Siegert W, Studer U, Tjulandin S, von der MH, Walz P, Weinknecht S, Weissbach L, Winter E, Wittekind C (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15: 1377–1399PubMedCrossRefGoogle Scholar
  99. Sleijfer S, Willemse PH, de Vries EG, van der Graaf WT, Schraffordt KH, Mulder NH (1996) Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis. Br J Cancer 74: 947–950PubMedGoogle Scholar
  100. Sonneveld DJ, Hoekstra HJ, van der Graaf WT, Sluiter WJ, Mulder NH, Willemse PH, Koop HS, Sleijfer DT (2001) Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 91: 1304–1315PubMedCrossRefGoogle Scholar
  101. Stephens AW, Gonin R, Hutchins GD, Einhorn LH (1996) Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 14: 1637–1641PubMedGoogle Scholar
  102. Steyerberg EW, Keizer HJ, Zwartendijk J, Van Rijk GL, Van Groeningen CJ, Habbema JD, Stoter G (1993) Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis. Br J Cancer 68: 195–200PubMedGoogle Scholar
  103. Steyerberg EW, Keizer HJ, Stoter G, Habbema JD (1994) Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections. Eur J Cancer 30A: 1231–1239PubMedCrossRefGoogle Scholar
  104. Steyerberg EW, Keizer HJ, Fossa SD, Sleijfer DT, Toner GC, Schraffordt KH, Mulders PF, Messemer JE, Ney K, Donohue JP (1995) Plediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 13: 1177–1187PubMedGoogle Scholar
  105. Steyerberg EW, Gerl A, Fossa SD, Sleijfer DT, De Wit R, Kirkels WJ, Schmeller N, Clemm C, Habbema JD, Keizer HJ (1998) Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol 16: 269–274PubMedGoogle Scholar
  106. Tait D, Peckham MJ, Hendry WF, Goldstraw P (1984) Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer 50: 601–609PubMedGoogle Scholar
  107. Toner GC, Panicek DM, Heelan RT, Geller NL, Lin SY, Bajorin D, Motzer RJ, Scher HI, Herr HW, Morse MJ (1990) Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 8: 1683–1694PubMedGoogle Scholar
  108. Toner GC, Stockler MR, Boyer MJ, Jones M, Thomson DB, Harvey VJ, Olver IN, Dhillon H, McMullen A, Gebski VJ, Levi JA, Simes RJ (2001) Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet 357: 739–745PubMedCrossRefGoogle Scholar
  109. Willan BD, McGowan DG (1985) Seminoma of the testis: a 22-year experience with radiation therapy. Int J Radiat Oncol Biol Phys 11: 1769–1775PubMedGoogle Scholar
  110. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316: 1435–1440PubMedCrossRefGoogle Scholar
  111. Wozniak AJ, Samson MK, Shah NT, Crawford ED, Ford CD, Altman SJ, Stephens RL, Natale RB, Bouroncle BA, Blumenstein BA (1991) A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study. J Clin Oncol 9: 70–76PubMedGoogle Scholar
  112. Xiao H, Mazumdar M, Bajorin DF, Sarosdy M, Vlamis V, Spicer J, Ferrara J, Bosl GJ, Motzer RJ (1997) Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol 15: 2553–2558PubMedGoogle Scholar
  113. Zon RT, Nichols C, Einhorn LH (1998) Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels. J Clin Oncol 16: 1294–1297PubMedGoogle Scholar

Literatur zu Kap. 26.11

  1. Albers P, Dommer K, Muller SC (1998) Hodentumoren. Todesfälle und Rezidive nach inadäquater Therapie. Urologe A 37: 625–628PubMedCrossRefGoogle Scholar
  2. Albers P, Ganz A, Hanning E et al. (2000) Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol 164: 381–384PubMedCrossRefGoogle Scholar
  3. André F, Fizazi K, Culine S, Droz JP, Taupin P, Lhommé C, Terrier-Lacombe MJ, Théodore C (2000) The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Europ J Cancer 36: 1389–1394CrossRefGoogle Scholar
  4. Beck SDW, Foster RS, Bihrle R, Einhorn LH, Donohue JP (2005) Outcome Analysis for Patients With Elevated Serum Tumor Markers at Postchemotherapy Retroperitoneal Lymph Node Dissection. J Clin Oncol 23:6149–6156PubMedCrossRefGoogle Scholar
  5. Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Pico JL, Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn LH, Siegert W (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic factors. J Clin Oncol 14:2638–2645PubMedGoogle Scholar
  6. Beyer J, Stenning S, Gerl A, Fossa S, Siegert W (2002) High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matchedpair analysis. Ann Oncol 13:599–605PubMedCrossRefGoogle Scholar
  7. Donadio AC, Motzer RJ, Bajorin DF, Kantoff PW, Sheinfeld J, Houldsworth J, Chaganti RSK, Bosl GJ (2003) Chemotherapy for teratoma with malignant transformation. J Clin Oncol 21: 4285–4291PubMedCrossRefGoogle Scholar
  8. Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R (2007) High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 357: 340–348PubMedCrossRefGoogle Scholar
  9. Farhat F, Culine S, Theodore C, Bekradda M, Terrier-Lacombe MJ, Droz JP (1996) Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients. Cancer 77: 1193–1197PubMedCrossRefGoogle Scholar
  10. Fossa SD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, Jones WG, Williams MV, Oliver RT, Newlands ES, Mead GM, Cullen MH, Kaye SB, Rustin GJS, Cook PA (1999) Prognostic factors in patients progressing after platinum-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 80: 1392–1399PubMedCrossRefGoogle Scholar
  11. Horwich A, Shipley J, Huddart R (2006) Testicular germ-cell cancer. Lancet 367: 754–765PubMedCrossRefGoogle Scholar
  12. George DW, Foster RS, Hromas RA, Robertson KA, Vance GH, Ulbright TM, Gobbett TA, Heiber DJ, Heerema NA, Ramsey HC, Thurston VC, Jung S-H, Shen J, Finch DE, Kelley MR, Einhorn LH (2003) Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol 21:113–122PubMedCrossRefGoogle Scholar
  13. Hartmann J, Schmoll HJ, Kuczyk MA, Candelaria M, Bokemeyer C (1997) Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Ann Oncol 8:531–538PubMedCrossRefGoogle Scholar
  14. Heidenreich A, Krege S, Flaßhove M (2004) Interdisziplinäre Kooperation in der Therapie von komplexen Patienten mit fortgeschrittenem testikulärem Keimzelltumor. Urol A 43:1521–1530CrossRefGoogle Scholar
  15. Heidenreich A, Ohlmann CH (2005) Metastasierte testikuläre Keimzelltumoren. Aktuelle Indikationen zur Residualtumorresektion nach induktiver ChemotherapieGoogle Scholar
  16. Heidenreich A, Ohlmann CH, Hegele A, Beyer J (2005) Repeat retroperitoneal lymphadenectomy in advanced testicular cancer. Eur Urol 47: 64–71PubMedCrossRefGoogle Scholar
  17. Hendry WF, Norman AR, Dearnaley DP, Fisher C, Nicholls J, Huddart RA, Horwich A (2002) Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 94: 1668–1676PubMedCrossRefGoogle Scholar
  18. Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marionv S, Sheinfeld J, Bosl GJ, Motzer RJ (2005) Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 23: 6549–6555PubMedCrossRefGoogle Scholar
  19. Krege S, Beyer J, Souchon R, Albers P (2008) European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I + II. Eur Urol 53: 478–513PubMedCrossRefGoogle Scholar
  20. Kuczyk MA, Bokemeyer C, Kollmannsberger C, Corvin C, Anastasias S, Machtens S, Merseburger A, Wegener G, Stenzel A, Hartmann JT, Jonas U (2004) Late relapse after treatment for nonseminomatous germ cell tumors according to a single center-based experience. World J Urol 22: 55–59PubMedCrossRefGoogle Scholar
  21. Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH (1998) Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16: 2500–2504PubMedGoogle Scholar
  22. Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IGH, Berdel BE, Weissinger F, Schleicher J, Egerer G, Haas, A, Schirren R, Beyer J, Bokemeyer C, Rick O (2007) Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol 25: 2778–2784PubMedCrossRefGoogle Scholar
  23. Lutke Holzik MF, Hoekstra HJ, Mulder NH, Suurmeijer AJH, Sleijfer DT, Gietema JA (2003) Non-germ cell malignancy in residual or recurrent mass after chemotherapy for nonseminomatous testicular germ cell tumor. Ann Surg Oncol 10: 131–135PubMedCrossRefGoogle Scholar
  24. Miller KD, Loehrer PJ, Gonin R, Einhorn LH (1997) Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol 15: 1427–1431PubMedGoogle Scholar
  25. Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M, Reich L, Flombaum C, Mariani T, Tong WP, Bosl GJ (2000) Sequential dose-intensive paclitaxel, ifosfamide, carboplatin and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 18: 1173–1180PubMedGoogle Scholar
  26. Murphy BR, Breeden ES, Donohue JP, Messemer J, Walsh W, Roth BJ, Einhorn LH (1993) Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 11: 324–329PubMedGoogle Scholar
  27. Pico JL, Rosti G, Kramar A, Wandt H, Koza V, Salvioni R, Theodore C, Lelli G, Siegert W, Horwich A, Marangolo M, Linkesch W, Pizzocaro G, Schmoll HJ, Bouzy J, Droz JP, Biron P (2005) A randomized trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors. Ann Oncol 16: 1152–1159PubMedCrossRefGoogle Scholar
  28. Porcu P, Bhatia S, Sharma M, Einhorn LH (2000) Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol 18: 1181–1186PubMedGoogle Scholar
  29. Rick O, Bokemeyer C, Weinknecht S, Schirren J, Pottek T, Hartmann JT, Braun T, Rachud B, Weißbach L, Hartmann M, Siegert W, Beyer J (2004) Residual tumor resection after high-dose chemotherapy in patients withrelapsed or refractory germ cell cancer. J Clin Oncol 22: 3713–3719PubMedCrossRefGoogle Scholar
  30. Saxman SB, Nichols CR, Einhorn LH (1994) Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience. J Clin Oncol 12: 1390–1393PubMedGoogle Scholar
  31. Schmoll HJ, Beyer J (1998) Prognostic factors in metastatic germ cell tumors. Semin Oncol 25: 174–185PubMedGoogle Scholar
  32. Shahidi M, Norman A, Nicholls J, Dearnaley D, Horwich A, Huddart R (2002) Late recurrence in 1263 men with testicular germ cell tumours: Multivariate analysis of risk factors and implications for management. Cancer 95: 520–30PubMedCrossRefGoogle Scholar
  33. Sharp DS, Carver BS, Eggener SE, Kondagunta GV, Motzer RJ, Bosl GJ, Sheinfeld J (2008) Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol 26: 5524–5529PubMedCrossRefGoogle Scholar
  34. Sonneveld DJ, Sleijfer DT, Koops HS, Keemers-Gels ME, Molenaar WM, Hoekstra HJ (1998) Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: a plea for an aggressive surgical approach. Cancer 82: 1343–1351PubMedCrossRefGoogle Scholar
  35. Stenning SP, Parkinson MC, Fisher C, Mead GM, Cook PA, Fossa SD, Horwich A, Jones WG, Newlands ES, Oliver RT, Stenwig AE, Wilkinson PM (1998) Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer 83:1409–1419PubMedCrossRefGoogle Scholar
  36. Vaena DA, Abonour R, Einhorn LH (2003) Long-term survival after high-dose salvage-chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol 21: 4100–4104PubMedCrossRefGoogle Scholar
  37. Vuky J, Tickoo SK, Sheinfeld J, Bacik J, Amsterdam A, Mazumdar M, Reuter V, Bajorin DF, Bosl GJ, Motzer RJ (2002) Salvage chemotherapy for patients with advanced pure seminoma. J Clin Oncol 20: 297–301PubMedCrossRefGoogle Scholar

Literatur zu Kap. 26.12 Mit * gekennzeichnete Literatur wurde für ◘ Tab. 26.24 ausgewertet

  1. Albers P, Siener R, Kliesch S, Weissbach L, Krege S, Sparwasser C, Schulze H, Heidenreich A, de Riese W, Loy V, Bierhoff E, Wittekind C, Fimmers R, Hartmann M; German Testicular Cancer Study Group (2003) Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group trial. J Clin Oncol 21 (8): 1505–1512PubMedCrossRefGoogle Scholar
  2. Albers P, Weinknecht S, Krege S, Kliesch S, Hartmann M, Heidenreich A, Walz P, Fimmers R (2004) Prediction of necrosis after chemotherapy of advanced germ cell tumors: Results of a prospective multicenter study of the GTCSG. J Urol 171(5): 1842–1843CrossRefGoogle Scholar
  3. American Institute for Cancer Research (1999) Protect yourself from testicular cancer. www.aicr.orgGoogle Scholar
  4. Balint E, Lubau-Plozza B (1975) Fünf Minuten pro Patient. Suhrkamp VerlagGoogle Scholar
  5. Bamberg M, Schmidberger H, Meisner C, Classen J, Souchon R, Weinknecht S, Schorscht J, Walter F, Engelhart-Cabillic R, Schulz D, Born H, Flink M (1999) Radiotherapy for stage I/IIA/IIB testicular seminoma. Int J Cancer 35: 293–298Google Scholar
  6. Baniel J Foster RS, Genin R, Messemer JE, Donohue JP, Einhorn LH (1995) Late relapse of Testicular cancer. J Clin Oncol 13 (5): 1170–1176PubMedGoogle Scholar
  7. Bokemeyer C, Nowak P, Haupt A, Metzner B, Köhne H, Hartmann JT, Kanz L, Schmoll HJ (1997) Treatment of brain metastasis in patients with testicular cancer. J Clin Oncol 15: 1449–1454PubMedGoogle Scholar
  8. Bosl GJ, Geller NL, Cirrincione C, Vogelsang NJ, Bosl GJ (1983) Multivariate analysis of Prognostic variables in patients with metastatic testicular cancer. Cancer Res 43: 3403–3407PubMedGoogle Scholar
  9. Bruns F, Bremer M, Meyer A, Karstens JH (2005) Adjuvant radiotherapy in stage I seminoma: Is there a role for further reduction of treatment volume? Acta Oncol 44: 142–148PubMedCrossRefGoogle Scholar
  10. Buchholz TA, Walden TL, Prestidge BR (1998) Cost-effectivness of post-treatment survival after radiation therapy of early stage seminoma. Cancer 82 (6): 1126–1133PubMedCrossRefGoogle Scholar
  11. Büttner R (2006) Psychotherapeutische Begleitung von Hodenkrebspatienten. Dyn Psychatrie, Heft 214/215Google Scholar
  12. Claßen, J, Souchon R, Schmidberger H, Spillner P, Hehr P, Bamberg M (2005) Ist Nachsorge (FU) nach adjuvanter Radiotherapie beim Seminom notwendig? Ergebnisse einer prospektiven Untersuchung an 675 Patienten. Strahlenther Oncol 181 (Suppl.1): 61Google Scholar
  13. Claßen J, Bamberg M, Schmidberger H, Souchon R, Hartmann JT, Weissbach L, Hartmann M, Spillner P, Lutterbach J, Hehr J (2006) What is the value of systematic follow-up in stage I seminoma after paraaotic radiotherapy? An analysis of the German Testicular Cancer Study Group (GTCSG) in 675 prospectively followed patients (in press)Google Scholar
  14. Clemm C, Bokemeyer C (1998) Therapie des fortgeschrittenen Seminom. Onkologie 4: 524–531CrossRefGoogle Scholar
  15. Dearnaley DP, Huddart RA, Horwich A (2001) Managing testicular cancer. BMJ 322: 1583–1588PubMedCrossRefGoogle Scholar
  16. Deutsche Krebsgesellschaft (2002) Leitlinie zur Diagnostk und Therapie von Hodentumoren auf der Grundlage evidenzbasierter Medizin (EBM). Hrsg R Souchon, H-J Schmoll, S Krege für die German Testicular Cancer Study Group im Auftrag der Deutschen Krebsgesellschaft. Zuckschwerdt, München Bern Wien New YorkGoogle Scholar
  17. Dieckmann K-P, Loy V (2003) False-negative biopsies for the diagnosis of testicular intra-epithelial neoplasia (TIN) — an update. Eur Urol 43 (5): 516–521PubMedCrossRefGoogle Scholar
  18. Dieckmann KP, Albers P, Classen J, de Witt M, Pichlmeier U, Rick O, Müllerleile U, Kuczyk M (2005) Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol 173: 824–829PubMedCrossRefGoogle Scholar
  19. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R (1993) Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965–1989. Br J Urol 71 (3): 326–335PubMedCrossRefGoogle Scholar
  20. Donohue JP, Thornhill JA, Forster RS, Bihrle R, Rowland R, Einhorn LA, Richie JP (1995) The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University Experience (1965 to 1989). J Urol 153 (1): 85–89PubMedCrossRefGoogle Scholar
  21. Fernandez EB, Colon E, McLeod DG, Moul JW (1994) Efficacy of radiographic chest imaging in patients with testicular cancer. Urology 44 (2): 243–249PubMedCrossRefGoogle Scholar
  22. Flechon A, Culine S, Theodore C, Droz J-P (2005) Pattern of relapse after first line treatment of advanced stage germ-cell tumors. Eur Urol 48: 957–964PubMedCrossRefGoogle Scholar
  23. Fleer J, Hoekstra HJ, Sleijfer DT, Hoekstra-Weebers JE (2004) Quality of live of survivors of testicular germ cell cancer: a review of the literature. Support Care Cancer 12 (7): 476–486PubMedCrossRefGoogle Scholar
  24. Fossa SD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, Jones WG, Williams MV, Oliver RT, Newlands ES, Mead GM, Cullen MH, Kaye SB, Rustin GJS, Cook PA (1999a) Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 80 (9): 1392–1399PubMedCrossRefGoogle Scholar
  25. Fossa SD, Horwich A, Russel JM, Roberts JT, Cullen MH, Hodson NJ, Jones WG, Yosef H, Duchesne GM, Owen JR, Grosch EJ, Chetiyawardana AD, Read NS, Widmer B, Stenning SP (1999b) Optimal planning target volume for stage I testicular seminoma: a Medical Re-search Council randomized trial. J Clin Oncol 17 (4): 1146–1154PubMedGoogle Scholar
  26. Fossa SD, Dahl AA, Haaland CF (1999c) Health-related quality of life in patients treated for testicular cancer. Curr Opin Urol 9 (5): 425–429PubMedCrossRefGoogle Scholar
  27. Fossa SD, Horwich A, Russel JM et al (1999d) Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. J Clin Oncol 17: 1146–54PubMedGoogle Scholar
  28. Fossa SD (2004) Long-term sequelae after cancer therapy. Acta Oncol 43 (2): 134–141PubMedCrossRefGoogle Scholar
  29. Gels ME, Hoekstra HJ, Sleijfer DT, Marrink J, de Bruin HWA, Molenaar WM, Freling NJ, Droste JHJ, Schraffordt Koops JH (1995) Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 13 (5): 1188–1194PubMedGoogle Scholar
  30. Gerl A, Clemm C, Schmeller N, Hartenstein R, Lamerz R, Willmanns W (1995) Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer 72: 1026–1032PubMedGoogle Scholar
  31. Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W (1997) Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 8: 41–47PubMedCrossRefGoogle Scholar
  32. Gerl A, Mühlbayer D, Hansmann G, Mraz W, Hiddemann W (2001) The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer 91 (7): 1297–1303PubMedCrossRefGoogle Scholar
  33. Gerl A, Barba M, Weiss M, Liedl B, Zimmermann F, Clemm C (2003). Hodentumoren. Manual Urogenitale Tumoren. Tumorzentrum München u. Zuckschwerdt, MünchenGoogle Scholar
  34. Gietema JA, Meinardi T, Sleijfer DT, Hoekstra HJ, van der Graaf WTA (2002) Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapie for disseminated nonseminomatous testicular cancer. Ann Oncol 13: 1616–1620PubMedCrossRefGoogle Scholar
  35. Gosse ON, Oosterhof, Verlind J (2004) Testicular tumours (nonseminomatous). BJU International 94: 1196–1201CrossRefGoogle Scholar
  36. Hartmann M, Büttner H, Dettmann R, Pottek T (1995) Atypische Metastasierungen von Keimzellzumoren. In: Schnorr D, Loening SA, Weißbach L (Hrsg) Hodentumoren. Testis Cancer. Blackwell, Berlin: 7–27Google Scholar
  37. Harvey ML, Geldart TR, Duell R, Mead GM, Tung K (2002) Routine computerised tomo-graphic scans of the thorax in surveillance in stage I testicular non-seminomatous germ-cell cancer — a necessary risk? Ann Oncol 13: 237–242PubMedCrossRefGoogle Scholar
  38. Hermans BP, Sweeney CJ, Foster RS, Einhorn LH, Donohue JP (2000) Risk of systemic metastasis in clinical stage I nonseminoma germ cell testis tumor managed by retro-peritoneal lymph node dissection. J Urol 163: 1724–1724CrossRefGoogle Scholar
  39. Horwich A, Norman A, Fisher C, Hendry WF, Nichols J, Dearneley DP (1994) Primary chemotherapie for stage II nonseminomatous germ cell tumors of the testis. J Urol 151: 72–78PubMedGoogle Scholar
  40. Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, Dearnaley DP (2003) Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21 (8): 1513–1523PubMedCrossRefGoogle Scholar
  41. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancer. J Clin Oncol 15: 594–603Google Scholar
  42. Jakob A, Kollmannsberger C, Kanz L, Bokemeyer C (1998) Spättoxizität nach Chemothera-pie maligner Hodentumoren. Urologe A 37: 635–647PubMedCrossRefGoogle Scholar
  43. Jewett MAS, Grabowski A, McKiernan J (2003) Management of recurrence and follow-up for cancer. Urol Clin N Am 30: 819–830CrossRefGoogle Scholar
  44. Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A, Stenning SP (2005) Randomized trial of 30 versus 20 gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council trial TE18, European Organisation for the Research and Treatment of Cancer trial 30942 (ISRCTN 18525328). J Clin Oncol 23 (6) 1200–1209PubMedCrossRefGoogle Scholar
  45. Kakehi Y, Kamoto T, Kawakita M, Ogawa O (2002) Follow-up of clinical stage I testicular cancer: cost and risk benefit considerations. Int J Urol 9 (3): 154–160PubMedCrossRefGoogle Scholar
  46. Kennedy BJ, Torkelson JL, Fraley EE (1994) Adjuvant chemotherapie for stage II nonsemi-nomatous germ cell cancer of the testis. Cancer 73: 1485–1489PubMedCrossRefGoogle Scholar
  47. Koch MO (1998) Cost-effectiv strategies for the follow-up of patients with germ cell tumors. Urol Clin N Am 25 (3): 495–502CrossRefGoogle Scholar
  48. Krege S, Beyer J, Souchon R et al. (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG). Eur Urol 53: 478–513PubMedCrossRefGoogle Scholar
  49. Laguna MP, Klepp O, Horwich A, Algaba F, Bokemeyer C, Pizzokaro G, Cohn-Cedemark G, Albers P (2004) Guidelines on testicular cancer. Update March 2004. European Association of UrologyGoogle Scholar
  50. Livsey JE, Taylor B, Mobarek N, Cooper RA, Carrington B, Logue JP (2001) Patterns of Relapse following radiotherapy for stage I seminoma of the testis: implications for follow-Up. Clin Oncol 13: 296–300Google Scholar
  51. Logue JP, Harris MA, Livsey JE, Swindell R, Mobarek N, Read G (2003) Short course para-aortic radiation for stage I seminoma of the testis. Int J Rad Oncol Biol Phys 57 (5): 1304–1309Google Scholar
  52. Mann K (1990) Tumor markers in testicular cancer. Urologe A 29 (2): 77–86PubMedGoogle Scholar
  53. Martin JM, Pnazarella T, Zwahlen DR et al. (2007) Evidence based guidelines for following stage I seminoma. Cancer 109:2248–56PubMedCrossRefGoogle Scholar
  54. Meinardi MT, Gietema JA, Van Veldhuisen DJ, Van der Graaf WTA, Van der Berg MP, Schraffordt Koops H, Willemse PHB, Mulder MH, De Vries EGE, Sleijfer DTh (1999) Treatment related cardiovascular morbidity in long-term survivors in metastatic testicular Cancer. Proc ASCO 18: 308a, Abstract 1182Google Scholar
  55. Montie JE (1994) Follow-up after radical orchiectomy for testicular cancer. Urol Clin N Am 21 (4): 757–760Google Scholar
  56. Nichols CR (1998) Testicular cancer. Curr Probl Cancer 22: 187–274PubMedCrossRefGoogle Scholar
  57. Oliver RTD, Edmonds RM, Ong JYH, Ostrowski M, Jackson AW, Baille-Johnson H, Williams MV, Wiltshire CR, Mott T, Pratt WR, Trask CLW, Hope-Stone HF (1994) Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy. Int J Rad Oncol Biol Phys 29 (1): 3–8Google Scholar
  58. Oliver RTD, Ong J, Shamash J, Ravi R, Nagund V, Harper P, Ostrowski MJ, Sizer B, Levay MJ, Robinson A, Neal DE, Williams M (2004) Long-term follow-up of anglian germ cell cancer group: surveillance versus patients with stage I nonseminoma treated with adjuvant chemotherapy. Urology 63 (3): 556–561PubMedCrossRefGoogle Scholar
  59. Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Jaffe JK, de Witt R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP; MRC TE19 collaborators and the EORTC 30982 collaborators (2005) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366 (9482): 293–300PubMedCrossRefGoogle Scholar
  60. Pont J, Albrecht W, Postner G, Sellner F, Angel K, Höltl W (1996) Adjuvant chemotherapie for high-risk stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 14 (2): 441–448PubMedGoogle Scholar
  61. Pottek TS, Diekmann KP (2005a) Nachsorge beim Hodentumor lohnt sich. Urologe 44: 1024–1030PubMedCrossRefGoogle Scholar
  62. Pottek TS, Hartmann M, Bokemeyer C (2005b) Nachsorge und Spättoxizitäten bei Hodentu-moren. Dt Ärzteblatt 102 (48): 2642–2646Google Scholar
  63. Roeleveld TA, Horenblas S, Meinhardt W, van de Vijver M, Kooi M, ten Bokkel Huinink WW (2001) Surveillance can be the standard of care of stage I nonseminomatous testicular Tumors and even high risk patients. J Urol 166: 2166–2170PubMedCrossRefGoogle Scholar
  64. Rustin GJ, Mead GM, Sally P et al. (2007) Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197 — The National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 10: 1310–1315CrossRefGoogle Scholar
  65. Sandon I, Larsson US, Eriksson C (2000) An interview study of men discovering testicular patients with nonseminoma testis cancer. Cancer Nurs 23 (4): 304–309CrossRefGoogle Scholar
  66. Schölermann KH, Dettmann R, Hartmann M (1996) Die risikogesteuerte Hodentumornach-sorge. Urologe A 35: 326–330PubMedGoogle Scholar
  67. Shahidi A, Norman R, Nicholls J, Dearnely DP, Huddart A, Horwich A (2000) How long to follow up patients with testicular germ cell tumours? Proc ASCO 19: Abstract 1300Google Scholar
  68. Sharir S, Foster RS, Donohue JP, Jewett MA (1996) What is the appropriate follow-up after treatment? Semin Urol Oncol 14 (1): 45–53PubMedGoogle Scholar
  69. Sharir S, Jewett MAS, Sturgeon JFG, Moore M, Warde PR, Catton CN, Gospodarowicz M (1999) Progression detection of stage I nonseminomatous testis cancer on surveillance: implicationf for the followup protocol. J Urol 161: 472–476PubMedCrossRefGoogle Scholar
  70. Sogani PC, Perotti M, Herr HW, Fair WR, Thaler HT, Bosl G (1998) Clinical stage I testis Cancer: long-term outcome of patients on surveillance. J Urol 159 (3): 855–858PubMedCrossRefGoogle Scholar
  71. Sonneveld DJA, Sleijfer DTh, Schraffordt Koops H, Keemers-Gels ME, Molenaar WM, Hoekstra HJ (1998) Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors. Cancer 82 (7): 1343–1351PubMedCrossRefGoogle Scholar
  72. Sonneveld DJA, Hoekstra HJ, van der Graaf WTA, Sluiter WJ, Mulder NH, Willemse PHB, Schraffordt PHB, Sleijfer DT (2001) Improved long term survival of patients with non-seminomatous germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 91 (7): 1304–1315PubMedCrossRefGoogle Scholar
  73. Spermon JR, Hoffmann AL, Horenblas S, Verbeek ALM, Witjes JA, Kiemeney LA (2005) The efficacy of different follow-up strategies in clinical stage I non-seminomatous germ cell cancer: a Markov simulation study. Eur Urol 48: 258–268PubMedCrossRefGoogle Scholar
  74. Stephenson AJ, Bosl GJ, Bajorin DF, Stasi J, Motzer RJ, Sheinfeld J (2005) Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcino-ma predominance and/or lymphovascular invasion. J Urol 174: 557–560PubMedCrossRefGoogle Scholar
  75. Strohmeyer T, Geiser M, Ackermann R, Mumperow E, Hartmann M (1988) Early and long-term toxicity in the managment of advanced testicular tumors. Eur Urol 15: 205–208PubMedGoogle Scholar
  76. Sweeney CJ, Hermans BP, Heilman DK, Foster RS, Donohue JP, Einhorn LH (2000) Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma-predominant tetis cancer. J Clin Oncol 18 (2): 358–362PubMedGoogle Scholar
  77. Taylor MB, Carrington BM, Livsey JE, Logue JP (2001) The effect of radiotherapie treatment changes on sites of relapse in stage I testicular seminoma. Clin Radiol 56: 116–119PubMedCrossRefGoogle Scholar
  78. Testicular Cancer Resource Center (2004) Testicular cancer treatments: After treatment. In: Bank D (ed) www.tcrc.acor.org/whatnow.htmlGoogle Scholar
  79. Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, Kohler BA, Pukkala E, Lynch CF, Andersson M, Bergfeldt K, Clarke EA, Wiklund T, Stoter G, Gospodarowicz M, Sturgeon J, Fraumeni JF, Boice JD Jr. (1997) Risk of second malignant Neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89: 1429–1439PubMedCrossRefGoogle Scholar
  80. Travis L, Anderson M, Holowaty E, Van Leeuwen F, Bergfeldt K, Lynch C, Kohler B, Wiklund R, Curtis H, Storm H, Clarke E, Hail P, Pukkala E, Sturgeon J, Boice J Jr., Gospodarowicz M, Stovall M, Gilbert E (1999) Risk of leukemia following radiotherapy and chemotherapy for testicular cancer. Proc ASCO 18: 308a, Abstract 1185Google Scholar
  81. Trigo JM, Tabernero IM, Paz-Ares J, Garcia-Liano IL, Mora J, Lianes P, Esteban E, Salvador R, Lopez-Lopez JJ, Cortes-Funes H (2001) Tumor markers at the time of re-currence in patients with germ cell tumors. Cancer 88: 162–168CrossRefGoogle Scholar
  82. Van Dijk MR, Steyerberg EW, Stenning SP, Dusseldorp E, Habbema JDF (2004) Survival of patients with nonseminomatous germ cell cancer: a review of the IGCC classification by Cox regression and recursive partitioning. Br J Cancer 90 (6): 1176–1183PubMedCrossRefGoogle Scholar
  83. Warde P, Gospodarowicz MK, Bannerjee D et al. (1997) Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol 157: 1705–1710PubMedCrossRefGoogle Scholar
  84. Warde P, Gospodarowicz M, Panzarella T, Catton C, Sturgeon J, Moore M, Jewett M (1998) Managment of stage II seminoma. J Clin Oncol 16 (1): 290–294PubMedGoogle Scholar
  85. Weissbach L, Boedefeld EA, Horstmann-Dubral B (1990) Surgical treatment of stage I non-seminomatous germ cell testis tumor. Eur Urol 17: 97–106PubMedGoogle Scholar
  86. Weissbach L, Bussar-Maatz R, Flechtner H, Pichlmeier U, Hartmann M, Keller L (2000) RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors. Eur Urol 37: 582–594PubMedCrossRefGoogle Scholar
  87. Williams SD, Stablein DM, Einhorn LH, Muggia FM, Weiss RB, Donohue JP, Paulson DF, Brunner KW, Jacobs EM, Spaulding JT (1987) Immediate chemotherapie versus observation with treatment at relapse in pathological stage II testicular cancer. N Eng J Med 317: 1433–1438CrossRefGoogle Scholar

Literatur zu Kap. 26.13

  1. Al-Agha OM, Axiotis CA (2007) An in-depth look at Leydig cell tumor of the testis. Arch Pathol Lab Med 131: 311–317PubMedGoogle Scholar
  2. Amin MB (2005) Selected other problematic testicular and paratesticular lesions: rete testis neoplasms and pseudotumors, mesothelial lesions and secondary tumors. Mod Pathol 18 Suppl 2: S131–145CrossRefGoogle Scholar
  3. Bitker MO, Leo JP, Jardin A & Chatelain C (1986) Rate testicular tumors Apropos of 15 cases. [Article in French] Ann Urol (Paris) 20: 238–243Google Scholar
  4. Bokemeyer C, Kuczyk M, Schoffski P, Schmoll HJ (1993) Familial occurrence of Leydig cell tumors: a report of a case in a father and his adult son. J Urol 150: 1509–10PubMedGoogle Scholar
  5. Bonkat G, Ruszat R, Forster T, Wyler S, Dogra VS, Bachmann A (2007) Benign space-occupying cysts in the testis. An overview. [Article in German]. Urologe A 46: 1697–1703PubMedCrossRefGoogle Scholar
  6. Carmignani L, Colombo R, Gadda F, Galasso G, Lania A, Palou J, Algaba F, Villavicencio H, Colpi GM, Decobelli O, Salvioni R, Pizzocaro G, Rigatti P, Rocco F (2007) Conservative surgical therapy for leydig cell tumor. J Urol 178: 507–511PubMedCrossRefGoogle Scholar
  7. Cho JH, Chang JC, Park BH, Lee JG, Son CH (2002) Sonographic and MR imaging findings of testicular epidermoid cysts. AJR Am J Roentgenol 178: 743–748PubMedGoogle Scholar
  8. Chomette G, Delcourt A, Auriol M (1985) Non germinal tumors of the testis. Prog Clin Biol Res 203: 35–45PubMedGoogle Scholar
  9. Colecchia M, Nistal M, Gonzalez-Peramato P, Carmignani L, Salvioni R, Nicolai N, Regadera J (2007) Leydig cell tumor and hyperplasia: a review. Anal Quant Cytol Histol 29: 139–47PubMedGoogle Scholar
  10. Datta MW, Ulbright TM, Young RH (2001) Renal cell carcinoma metastatic to the testis and its adnexa: a report of five cases including three that accounted for the initial clinical presentation. Int J Surg Pathol 9: 49–56PubMedCrossRefGoogle Scholar
  11. Dieckmann KP (1991) Pathogenese und Frühdiagnostik der germinalen Hodentumoren Habilitationsschrift. Freie Universität Berlin Fachbereich Medizin, BerlinGoogle Scholar
  12. Dieckmann KP, Düe W, Loy V (1988) Intrascrotal metastasis of renal cell carcinoma Case report and review of the literature. Eur Urol 15: 297–301PubMedGoogle Scholar
  13. Dieckmann KP, Loy V (1993) Metachronous germ-cell and Leydig cell tumors of the testis Do testicular germ cell tumors and Leydig cell tumors share risk factors? Cancer 72: 1305–1307PubMedCrossRefGoogle Scholar
  14. Dieckmann KP, Loy V (1994a) Epidermoid cyst of the testis: A review of clinical and histogenetic considerations. Br J Urol 73: 436–441PubMedCrossRefGoogle Scholar
  15. Dieckmann KP, Loy V (1994b) Response of metastasized sex cord gonadal stromal tumor of the testis to cisplatin-based chemotherapy. J Urol 151: 1024–1026PubMedGoogle Scholar
  16. Düe W, Dieckmann KP, Niedobitek G, Bornhöft G, Loy V, Stein H (1990) Testicular sex cord stromal tumour with granulosa cell differentiation: detection of steroid hormone receptors as a possible basis for tumour development and therapeutic management. J Clin Pathol 43: 732–737PubMedCrossRefGoogle Scholar
  17. Dutt N, Bates AW, Baithun SI (2000) Secondary neoplasms of the male genital tract with different patterns of involvement in adults and children Histopathology 37: 323–331PubMedCrossRefGoogle Scholar
  18. Eble JN, Sauter G, Epstein JI, Sesterhenn IAE (2004) World health Organization Classification of tumours Pathology, Genetics Tumours of the Urinary System and Male Genital Organs. IARC Press, LyonGoogle Scholar
  19. Emerson RE, Ulbright TM (2007) Morphological approach to tumours of the testis and paratestis. J Clin Pathol 60: 866–880PubMedCrossRefGoogle Scholar
  20. Fischer D, Kurth KH, Löhr J (1975) Die Bedeutung der histologischen Diagnostik für die Behandlung der Hodentumoren. Z Urol Nephrol 67: 465–472Google Scholar
  21. Friedrichs R, Rübben H, Lutzeyer W (1986) Differential diagnosis and therapy of rare testicular tumors. Eur Urol 12: 217–223PubMedGoogle Scholar
  22. Giannarini G, Mogorovich A, Menchini Fabris F, Morelli G, De Maria M, Manassero F, Loggini B, Pingitore R, Cavazzana A, Selli C (2007) Long-term followup after elective testis sparing surgery for Leydig cell tumors: a single center experience. J Urol 178: 872–6; quiz 1129PubMedCrossRefGoogle Scholar
  23. Hammerich KH, Hille S, Ayala GE, Wheeler TM, Engers R, Ackermann R, Mueller-Mattheis V (2008) Malignant advanced granulosa cell tumor of the adult testis: case report and review of the literature. Hum Pathol 39: 701–709PubMedCrossRefGoogle Scholar
  24. Harzmann R, Stiens R (1982) Intraskrotale nichtgerminale Tumoren In Register und Verbundstudie für Hodentumoren — Bonn. In: Weißbach L, Hildenbrand G (Hrsg) Zuckschwerdt, München, S 306–339Google Scholar
  25. Hasselblom S, Ridell B, Wedel H, Norrby K, Sender Baum M, Ekman T (2004) Testicular lymphoma — a retrospective population-based clinical and immunohistochemical study. Acta Oncol 43: 758–765PubMedCrossRefGoogle Scholar
  26. Heidenreich A, Zumbe J, Vorreuther R, Klotz T, Vietsch H, Engelmann UH (1996) Testikuläre Epidermiszyste: Orchiektomie oder Enukleationsresektion? Urologe A 35: 1–5PubMedGoogle Scholar
  27. Heidrich A, Bollmann R, Knipper A (1999) Hodenmetastase eines Prostatakarzinoms drei Jahre nach subkapsulärer Orchiektomie. Urologe A 38: 279–281PubMedCrossRefGoogle Scholar
  28. Hoepffner W, Horn LC, Simon E, Sauerbrei G, Schroder H, Thamm-Mucke B, Bennek J, Kiess W (2005) Gonadoblastomas in 5 patients with 46XY gonadal dysgenesis. Exp Clin Endocrinol Diabetes 113: 231–235PubMedCrossRefGoogle Scholar
  29. Huyghe E, Nohra J, Vezzozi D, Daudin M, Bennet A, Caron P, Thonneau P, Plante P (2007) Fertility before and after treatment of patients with Leydig cell tumour. [Article in French]. Prog Urol 17: 841–845PubMedGoogle Scholar
  30. Jorgensen N, Muller J, Jaubert F, Clausen OP, Skakkebaek NE (1997) Heterogeneity of gonadoblastoma germ cells: similarities with immature germ cells spermatogonia and testicular carcinoma in situ cells. Histopathology 30: 177–86PubMedCrossRefGoogle Scholar
  31. Kersemaekers AM, Honecker F, Stoop H, Cools M, Molier M, Wolffenbuttel K, Bokemeyer C, Li Y, Lau YF, Oosterhuis JW, Looijenga LH (2005) Identification of germ cells at risk for neoplastic transformation in gonadoblastoma: an immunohistochemical study for OCT3/4 and TSPY. Hum Pathol 36: 512–521PubMedCrossRefGoogle Scholar
  32. Kim I, Young RH, Scully RE (1985) Leydig cell tumors of the testis A clinicopathological analysis of 40 cases and review of the literature. Am J Surg Pathol 9: 177–192PubMedCrossRefGoogle Scholar
  33. Krag Jacobsen G, Talerman A (1989) Atlas of germ cell tumors. Munksgaard, CopenhagenGoogle Scholar
  34. Kressel K, Schnell D, Dettmann R, Hartmann M, Butz M (1993) Diagnostik und Therapie nichtgerminaler Hodentumoren Organerhalt oder Orchiektomie? Urologe A 32: 237–241PubMedGoogle Scholar
  35. Lawrence WD, Young RH, Scully RE (1986) Sex Cord — Stromal Tumors In Pathology of the testis and its adnexa. In: Talerman A, Roth LM (eds) Churchill Livingstone, New York, pp 67–92Google Scholar
  36. Loy V, Linke J (2003) Endokrine Tumoren des Hodens. Pathologe 24: 308–313PubMedCrossRefGoogle Scholar
  37. Masur Y, Steffens J, Ziegler M, Remberger K (1996) Leydigzell-Tumoren des Hodens — klinische und morphologische Aspekte. Urologe A 35: 468–471PubMedCrossRefGoogle Scholar
  38. Mehra BR, Thawait AP, Narang RR, Gangane NM, Vyas VJ (2007) Adenocarcinoma of the rete testis with uncommon presentation as haematocele. Singapore Med J 48: e311–313PubMedGoogle Scholar
  39. Mikuz G, Kiesler J, Scheiber K, Dietze O (1984) Morphology and incidence of testicular tumors in western Austria (1945–1980). Zentralbl Allg Pathol 129: 91–100PubMedGoogle Scholar
  40. Mikuz G, Colecchia M (2007) Tumors of the testis and paratesticular structures. In: Mikuz G (ed) Clinical pathology of urologic tumors. pp 161–214. Informa Healthcare, LondonGoogle Scholar
  41. Mostofi FK, Price EB (1973) Tumors of the male genital system Atlas of tumor pathology Second series Fascicle 8. Armed Forces Institute of Pathology: WashingtonGoogle Scholar
  42. Petersen RO (1992) Urologic Pathology. Lippincott, PhiladelphiaGoogle Scholar
  43. Pugh RCB (1976) Pathology of the testis. Blackwell, OxfordGoogle Scholar
  44. Rosales Bordes A, Montlleo Gonzalez M, Villavicencio Mavrich H, Algaba Arrea F (2000) Metastatic testicular carcinoma. [Article in Spanish] Arch Esp Urol 53: 469–471PubMed